Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,9643620,renal clearances,"After intravenous administration, renal clearances of bambuterol and terbutaline were similar (about 140 ml min(-1)), but there was a five-fold difference in total clearance (bambuterol 1.25 l min(-1), terbutaline 0.23 l min(-1)).",Pharmacokinetics of bambuterol in healthy subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9643620/),[ml] / [min],140,3547,DB00871,Terbutaline
,9643620,total clearance,"After intravenous administration, renal clearances of bambuterol and terbutaline were similar (about 140 ml min(-1)), but there was a five-fold difference in total clearance (bambuterol 1.25 l min(-1), terbutaline 0.23 l min(-1)).",Pharmacokinetics of bambuterol in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9643620/),[l] / [min],1.25,3548,DB00871,Terbutaline
,9643620,total clearance,"After intravenous administration, renal clearances of bambuterol and terbutaline were similar (about 140 ml min(-1)), but there was a five-fold difference in total clearance (bambuterol 1.25 l min(-1), terbutaline 0.23 l min(-1)).",Pharmacokinetics of bambuterol in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9643620/),[l] / [min],0.23,3549,DB00871,Terbutaline
,9643620,Volume of distribution (Vss),Volume of distribution (Vss) was 1.6 l kg(-1) b.w. for both substances.,Pharmacokinetics of bambuterol in healthy subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9643620/),[l] / [kg],1.6,3550,DB00871,Terbutaline
,9643620,renal clearance,A similar renal clearance of bambuterol was found during oral administration but that of terbutaline decreased (to about 120 ml min(-1)).,Pharmacokinetics of bambuterol in healthy subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9643620/),[ml] / [min],120,3551,DB00871,Terbutaline
,9643620,terminal half-life,"Mean terminal half-life of bambuterol was 2.6 h after intravenous and 12 h after oral administration, implying that uptake was rate-limiting.",Pharmacokinetics of bambuterol in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9643620/),h,2.6,3552,DB00871,Terbutaline
,9643620,terminal half-life,"Mean terminal half-life of bambuterol was 2.6 h after intravenous and 12 h after oral administration, implying that uptake was rate-limiting.",Pharmacokinetics of bambuterol in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9643620/),h,12,3553,DB00871,Terbutaline
,9643620,Mean residence time,Mean residence time of terbutaline generated from oral bambuterol was 34 h compared with 8.0 h when terbutaline as such was infused.,Pharmacokinetics of bambuterol in healthy subjects. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9643620/),h,34,3554,DB00871,Terbutaline
,9643620,Mean residence time,Mean residence time of terbutaline generated from oral bambuterol was 34 h compared with 8.0 h when terbutaline as such was infused.,Pharmacokinetics of bambuterol in healthy subjects. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9643620/),h,8.0,3555,DB00871,Terbutaline
,9643620,bioavailability,Generated terbutaline had a bioavailability of 36% (28-46) after intravenous and 10.2% (6.1-13.2) after oral administration of the prodrug.,Pharmacokinetics of bambuterol in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9643620/),%,36,3556,DB00871,Terbutaline
,9643620,bioavailability,Generated terbutaline had a bioavailability of 36% (28-46) after intravenous and 10.2% (6.1-13.2) after oral administration of the prodrug.,Pharmacokinetics of bambuterol in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9643620/),%,10.2,3557,DB00871,Terbutaline
,9643620,peak: trough ratio,"The plasma concentration ofterbutaline fluctuated little during repeated oral administration (mean peak: trough ratio 1.9), as a result of prolonged absorption of bambuterol and slow formation of terbutaline.",Pharmacokinetics of bambuterol in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9643620/),,1.9,3558,DB00871,Terbutaline
,7223435,plasma concentrations,"Terbutaline sulphate 24 microgram kg-1 and aminophylline 52 mg kg-1 (7.42 . 10(-8) and 2.37 . 10(-4) mol kg-1 respectively) were given by a bolus intravenous injection, producing plasma concentrations in the range 0-15 ng terbutaline sulphate per ml (0-46 nanomol 1(-1)) and 10-85 microgram theophylline per ml (50-429 mumol 1(-1)).",Pharmacokinetics of terbutaline and theophylline in guinea pigs when administered simultaneously. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7223435/),ng,0-15,7099,DB00871,Terbutaline
,7223435,plasma concentrations,"Terbutaline sulphate 24 microgram kg-1 and aminophylline 52 mg kg-1 (7.42 . 10(-8) and 2.37 . 10(-4) mol kg-1 respectively) were given by a bolus intravenous injection, producing plasma concentrations in the range 0-15 ng terbutaline sulphate per ml (0-46 nanomol 1(-1)) and 10-85 microgram theophylline per ml (50-429 mumol 1(-1)).",Pharmacokinetics of terbutaline and theophylline in guinea pigs when administered simultaneously. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7223435/),nM,0-46,7100,DB00871,Terbutaline
,7223435,plasma concentrations,"Terbutaline sulphate 24 microgram kg-1 and aminophylline 52 mg kg-1 (7.42 . 10(-8) and 2.37 . 10(-4) mol kg-1 respectively) were given by a bolus intravenous injection, producing plasma concentrations in the range 0-15 ng terbutaline sulphate per ml (0-46 nanomol 1(-1)) and 10-85 microgram theophylline per ml (50-429 mumol 1(-1)).",Pharmacokinetics of terbutaline and theophylline in guinea pigs when administered simultaneously. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7223435/),μg,10-85,7101,DB00871,Terbutaline
,7223435,plasma concentrations,"Terbutaline sulphate 24 microgram kg-1 and aminophylline 52 mg kg-1 (7.42 . 10(-8) and 2.37 . 10(-4) mol kg-1 respectively) were given by a bolus intravenous injection, producing plasma concentrations in the range 0-15 ng terbutaline sulphate per ml (0-46 nanomol 1(-1)) and 10-85 microgram theophylline per ml (50-429 mumol 1(-1)).",Pharmacokinetics of terbutaline and theophylline in guinea pigs when administered simultaneously. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7223435/),μM,50-429,7102,DB00871,Terbutaline
,3225756,is,"For unknown reasons, the isotope ratio was higher for women (1.07) than for men (1.00).",Comparative pharmacokinetics of unlabeled and deuterium-labeled terbutaline: demonstration of a small isotope effect. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3225756/),,1.07,10785,DB00871,Terbutaline
,3225756,is,"For unknown reasons, the isotope ratio was higher for women (1.07) than for men (1.00).",Comparative pharmacokinetics of unlabeled and deuterium-labeled terbutaline: demonstration of a small isotope effect. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3225756/),,1.00,10786,DB00871,Terbutaline
,18518793,Retention,"Retention in lung tissues at the end of the perfusion period expressed as fraction of deposited dose was 0.19 +/- 0.05, 0.19 +/- 0.06, and 0.04 +/- 0.01 (mean +/- SD, n = 3) for budesonide, formoterol, and terbutaline, respectively.","Short inhalation exposures of the isolated and perfused rat lung to respirable dry particle aerosols; the detailed pharmacokinetics of budesonide, formoterol, and terbutaline. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18518793/),,0.19,14022,DB00871,Terbutaline
,18518793,Retention,"Retention in lung tissues at the end of the perfusion period expressed as fraction of deposited dose was 0.19 +/- 0.05, 0.19 +/- 0.06, and 0.04 +/- 0.01 (mean +/- SD, n = 3) for budesonide, formoterol, and terbutaline, respectively.","Short inhalation exposures of the isolated and perfused rat lung to respirable dry particle aerosols; the detailed pharmacokinetics of budesonide, formoterol, and terbutaline. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18518793/),,0.19,14023,DB00871,Terbutaline
,18518793,Retention,"Retention in lung tissues at the end of the perfusion period expressed as fraction of deposited dose was 0.19 +/- 0.05, 0.19 +/- 0.06, and 0.04 +/- 0.01 (mean +/- SD, n = 3) for budesonide, formoterol, and terbutaline, respectively.","Short inhalation exposures of the isolated and perfused rat lung to respirable dry particle aerosols; the detailed pharmacokinetics of budesonide, formoterol, and terbutaline. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18518793/),,0.04,14024,DB00871,Terbutaline
,18518793,fraction of deposited dose,"Retention in lung tissues at the end of the perfusion period expressed as fraction of deposited dose was 0.19 +/- 0.05, 0.19 +/- 0.06, and 0.04 +/- 0.01 (mean +/- SD, n = 3) for budesonide, formoterol, and terbutaline, respectively.","Short inhalation exposures of the isolated and perfused rat lung to respirable dry particle aerosols; the detailed pharmacokinetics of budesonide, formoterol, and terbutaline. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18518793/),,0.19,14025,DB00871,Terbutaline
,18518793,fraction of deposited dose,"Retention in lung tissues at the end of the perfusion period expressed as fraction of deposited dose was 0.19 +/- 0.05, 0.19 +/- 0.06, and 0.04 +/- 0.01 (mean +/- SD, n = 3) for budesonide, formoterol, and terbutaline, respectively.","Short inhalation exposures of the isolated and perfused rat lung to respirable dry particle aerosols; the detailed pharmacokinetics of budesonide, formoterol, and terbutaline. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18518793/),,0.19,14026,DB00871,Terbutaline
,18518793,fraction of deposited dose,"Retention in lung tissues at the end of the perfusion period expressed as fraction of deposited dose was 0.19 +/- 0.05, 0.19 +/- 0.06, and 0.04 +/- 0.01 (mean +/- SD, n = 3) for budesonide, formoterol, and terbutaline, respectively.","Short inhalation exposures of the isolated and perfused rat lung to respirable dry particle aerosols; the detailed pharmacokinetics of budesonide, formoterol, and terbutaline. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18518793/),,0.04,14027,DB00871,Terbutaline
,10839906,time to first response,"The time to first response to train-of-four nerve stimulation was 15 min (range, 9-21 min) and 59 min (range, 32-179 min) in patients receiving placebo and bambuterol, respectively.",The influence of drug-induced low plasma cholinesterase activity on the pharmacokinetics and pharmacodynamics of mivacurium. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10839906/),min,15,20800,DB00871,Terbutaline
,10839906,time to first response,"The time to first response to train-of-four nerve stimulation was 15 min (range, 9-21 min) and 59 min (range, 32-179 min) in patients receiving placebo and bambuterol, respectively.",The influence of drug-induced low plasma cholinesterase activity on the pharmacokinetics and pharmacodynamics of mivacurium. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10839906/),min,59,20801,DB00871,Terbutaline
,27167471,Area under the serum concentration-time curve within the first 6 h,Area under the serum concentration-time curve within the first 6 h was higher for EX (27 ± 3 ng/mL/h) (P ≤ 0.01) and EXH (25 ± 4 ng/mL/h) (P ≤ 0.05) than for R (20 ± 3 ng/mL/h).,Influence of exercise in normal and hot ambient conditions on the pharmacokinetics of inhaled terbutaline in trained men. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27167471/),[ng] / [h·ml],27,23694,DB00871,Terbutaline
,27167471,Area under the serum concentration-time curve within the first 6 h,Area under the serum concentration-time curve within the first 6 h was higher for EX (27 ± 3 ng/mL/h) (P ≤ 0.01) and EXH (25 ± 4 ng/mL/h) (P ≤ 0.05) than for R (20 ± 3 ng/mL/h).,Influence of exercise in normal and hot ambient conditions on the pharmacokinetics of inhaled terbutaline in trained men. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27167471/),[ng] / [h·ml],25,23695,DB00871,Terbutaline
,27167471,Area under the serum concentration-time curve within the first 6 h,Area under the serum concentration-time curve within the first 6 h was higher for EX (27 ± 3 ng/mL/h) (P ≤ 0.01) and EXH (25 ± 4 ng/mL/h) (P ≤ 0.05) than for R (20 ± 3 ng/mL/h).,Influence of exercise in normal and hot ambient conditions on the pharmacokinetics of inhaled terbutaline in trained men. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27167471/),[ng] / [h·ml],20,23696,DB00871,Terbutaline
,6586479,recovery,The recovery of [3H]terbutaline from serum and urine was 96.1 +/- 0.7 (mean +/- SEM) in the concentration range 1-250 ng/mL.,Assay of tritium-labelled terbutaline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6586479/),,96.1,24256,DB00871,Terbutaline
,3770288,Peak plasma levels attained,"Peak plasma levels attained (2.8 +/- 0.8 ng/ml), the time to peak plasma concentration (1.0 +/- 0.3 hr) and the elimination half-life (2.4 +/- 0.4 hr) were generally unchanged from the first to the final study dose.",Pharmacokinetics of the bronchodilator tulobuterol in man after repeated oral doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3770288/),[ng] / [ml],2.8,26270,DB00871,Terbutaline
,3770288,time to peak plasma concentration,"Peak plasma levels attained (2.8 +/- 0.8 ng/ml), the time to peak plasma concentration (1.0 +/- 0.3 hr) and the elimination half-life (2.4 +/- 0.4 hr) were generally unchanged from the first to the final study dose.",Pharmacokinetics of the bronchodilator tulobuterol in man after repeated oral doses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3770288/),h,1.0,26271,DB00871,Terbutaline
,3770288,elimination half-life,"Peak plasma levels attained (2.8 +/- 0.8 ng/ml), the time to peak plasma concentration (1.0 +/- 0.3 hr) and the elimination half-life (2.4 +/- 0.4 hr) were generally unchanged from the first to the final study dose.",Pharmacokinetics of the bronchodilator tulobuterol in man after repeated oral doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3770288/),h,2.4,26272,DB00871,Terbutaline
,23960758,T 0.5,"In both matrices, rapid degradation of drug favored and the T 0.5 of drug ranged from 9.92 to 12.41 h at 4 °C and from 6.31 to 9.13 h at 20 °C.",A validated HPTLC method for determination of terbutaline sulfate in biological samples: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23960758/),h,9.92 to 12.41,31765,DB00871,Terbutaline
,23960758,T 0.5,"In both matrices, rapid degradation of drug favored and the T 0.5 of drug ranged from 9.92 to 12.41 h at 4 °C and from 6.31 to 9.13 h at 20 °C.",A validated HPTLC method for determination of terbutaline sulfate in biological samples: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23960758/),h,6.31 to 9.13,31766,DB00871,Terbutaline
,23960758,maximum plasma concentration (Cpmax),"The maximum plasma concentration (Cpmax) was found to be 5875.03 ± 114 ng mL(-1), which is significantly higher than the maximum saliva concentration (Csmax, 1501.69 ± 96 ng mL(-1)).",A validated HPTLC method for determination of terbutaline sulfate in biological samples: Application to pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23960758/),[ng] / [ml],5875.03,31767,DB00871,Terbutaline
,23960758,maximum saliva concentration (Csmax,"The maximum plasma concentration (Cpmax) was found to be 5875.03 ± 114 ng mL(-1), which is significantly higher than the maximum saliva concentration (Csmax, 1501.69 ± 96 ng mL(-1)).",A validated HPTLC method for determination of terbutaline sulfate in biological samples: Application to pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23960758/),[ng] / [ml],1501.69,31768,DB00871,Terbutaline
,6586478,serum concentration curve,The mean serum concentration curve reached its maximum of 3.0 +/- 0.3 (SEM) ng/mL at 60-90 min.,Oral administration of terbutaline in asthmatic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6586478/),[ng] / [ml],3.0,31879,DB00871,Terbutaline
,19443162,LOD,"The calculated LOD and LOQ for salbutamol using a 1 mL urine sample were 4.0 and 12.12 microg/L for USAL, and 4.80 and 14.56 microg/L for USALMET, respectively.",New HPLC assay for urinary salbutamol concentrations in samples collected post-inhalation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19443162/),[μg] / [l],4.0,32282,DB00871,Terbutaline
,19443162,LOD,"The calculated LOD and LOQ for salbutamol using a 1 mL urine sample were 4.0 and 12.12 microg/L for USAL, and 4.80 and 14.56 microg/L for USALMET, respectively.",New HPLC assay for urinary salbutamol concentrations in samples collected post-inhalation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19443162/),[μg] / [l],12.12,32283,DB00871,Terbutaline
,19443162,LOD,"The calculated LOD and LOQ for salbutamol using a 1 mL urine sample were 4.0 and 12.12 microg/L for USAL, and 4.80 and 14.56 microg/L for USALMET, respectively.",New HPLC assay for urinary salbutamol concentrations in samples collected post-inhalation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19443162/),[μg] / [l],4.80,32284,DB00871,Terbutaline
,19443162,LOD,"The calculated LOD and LOQ for salbutamol using a 1 mL urine sample were 4.0 and 12.12 microg/L for USAL, and 4.80 and 14.56 microg/L for USALMET, respectively.",New HPLC assay for urinary salbutamol concentrations in samples collected post-inhalation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19443162/),[μg] / [l],14.56,32285,DB00871,Terbutaline
,19443162,LOQ,"The calculated LOD and LOQ for salbutamol using a 1 mL urine sample were 4.0 and 12.12 microg/L for USAL, and 4.80 and 14.56 microg/L for USALMET, respectively.",New HPLC assay for urinary salbutamol concentrations in samples collected post-inhalation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19443162/),[μg] / [l],12.12,32286,DB00871,Terbutaline
,19443162,LOQ,"The calculated LOD and LOQ for salbutamol using a 1 mL urine sample were 4.0 and 12.12 microg/L for USAL, and 4.80 and 14.56 microg/L for USALMET, respectively.",New HPLC assay for urinary salbutamol concentrations in samples collected post-inhalation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19443162/),[μg] / [l],14.56,32287,DB00871,Terbutaline
,19443162,recoveries,The mean (RSD) SPE recoveries of salbutamol were 90.82% (2.32%) for USAL and 91.54% (2.96%) for USALMET.,New HPLC assay for urinary salbutamol concentrations in samples collected post-inhalation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19443162/),%,90.82,32288,DB00871,Terbutaline
,19443162,recoveries,The mean (RSD) SPE recoveries of salbutamol were 90.82% (2.32%) for USAL and 91.54% (2.96%) for USALMET.,New HPLC assay for urinary salbutamol concentrations in samples collected post-inhalation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19443162/),%,91.54,32289,DB00871,Terbutaline
,19182395,clearances,"The theophylline clearances in males and females were 56.2+/-15.4 and 50.1+/-14.2 ml/h/kg for ages 0.5-<2 years, 58.7+/-18.8 and 48.3+/-6.5 ml/h/kg for ages 2-<4 years, and 65.7+/-12.0 and 52.1+/-16.8 ml/h/kg for ages 4-<9 years, respectively.",Effect of gender on theophylline clearance in the asthmatic acute phase in Japanese pediatric patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19182395/),[ml] / [h·kg],56.2,33222,DB00871,Terbutaline
,19182395,clearances,"The theophylline clearances in males and females were 56.2+/-15.4 and 50.1+/-14.2 ml/h/kg for ages 0.5-<2 years, 58.7+/-18.8 and 48.3+/-6.5 ml/h/kg for ages 2-<4 years, and 65.7+/-12.0 and 52.1+/-16.8 ml/h/kg for ages 4-<9 years, respectively.",Effect of gender on theophylline clearance in the asthmatic acute phase in Japanese pediatric patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19182395/),[ml] / [h·kg],50.1,33223,DB00871,Terbutaline
,19182395,clearances,"The theophylline clearances in males and females were 56.2+/-15.4 and 50.1+/-14.2 ml/h/kg for ages 0.5-<2 years, 58.7+/-18.8 and 48.3+/-6.5 ml/h/kg for ages 2-<4 years, and 65.7+/-12.0 and 52.1+/-16.8 ml/h/kg for ages 4-<9 years, respectively.",Effect of gender on theophylline clearance in the asthmatic acute phase in Japanese pediatric patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19182395/),[ml] / [h·kg],58.7,33224,DB00871,Terbutaline
,19182395,clearances,"The theophylline clearances in males and females were 56.2+/-15.4 and 50.1+/-14.2 ml/h/kg for ages 0.5-<2 years, 58.7+/-18.8 and 48.3+/-6.5 ml/h/kg for ages 2-<4 years, and 65.7+/-12.0 and 52.1+/-16.8 ml/h/kg for ages 4-<9 years, respectively.",Effect of gender on theophylline clearance in the asthmatic acute phase in Japanese pediatric patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19182395/),[ml] / [h·kg],48.3,33225,DB00871,Terbutaline
,19182395,clearances,"The theophylline clearances in males and females were 56.2+/-15.4 and 50.1+/-14.2 ml/h/kg for ages 0.5-<2 years, 58.7+/-18.8 and 48.3+/-6.5 ml/h/kg for ages 2-<4 years, and 65.7+/-12.0 and 52.1+/-16.8 ml/h/kg for ages 4-<9 years, respectively.",Effect of gender on theophylline clearance in the asthmatic acute phase in Japanese pediatric patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19182395/),[ml] / [h·kg],65.7,33226,DB00871,Terbutaline
,19182395,clearances,"The theophylline clearances in males and females were 56.2+/-15.4 and 50.1+/-14.2 ml/h/kg for ages 0.5-<2 years, 58.7+/-18.8 and 48.3+/-6.5 ml/h/kg for ages 2-<4 years, and 65.7+/-12.0 and 52.1+/-16.8 ml/h/kg for ages 4-<9 years, respectively.",Effect of gender on theophylline clearance in the asthmatic acute phase in Japanese pediatric patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19182395/),[ml] / [h·kg],52.1,33227,DB00871,Terbutaline
,2565392,apparent IC50,"The apparent IC50 values varied between 42 and 68 ng/ml (mean, 54 ng/ml) for metoprolol and between 3.6 and 4.7 ng/ml (mean, 4.1 ng/ml) for oxprenolol.",A nonsteady-state agonist antagonist interaction model using plasma potassium concentrations to quantify the beta-2 selectivity of beta blockers. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2565392/),[ng] / [ml],42 and 68,35946,DB00871,Terbutaline
,2565392,apparent IC50,"The apparent IC50 values varied between 42 and 68 ng/ml (mean, 54 ng/ml) for metoprolol and between 3.6 and 4.7 ng/ml (mean, 4.1 ng/ml) for oxprenolol.",A nonsteady-state agonist antagonist interaction model using plasma potassium concentrations to quantify the beta-2 selectivity of beta blockers. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2565392/),[ng] / [ml],54,35947,DB00871,Terbutaline
,2565392,apparent IC50,"The apparent IC50 values varied between 42 and 68 ng/ml (mean, 54 ng/ml) for metoprolol and between 3.6 and 4.7 ng/ml (mean, 4.1 ng/ml) for oxprenolol.",A nonsteady-state agonist antagonist interaction model using plasma potassium concentrations to quantify the beta-2 selectivity of beta blockers. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2565392/),[ng] / [ml],4.1,35948,DB00871,Terbutaline
,26639828,Cmax,The Cmax was 2.09 ng/mL at 16.0 h for a 0.2 mg/kg patch and 4.85 ng/mL at 13.6 h for a 0.4 mg/kg patch.,"The pharmacokinetics of the β2-adrenoceptor agonist, tulobuterol, in Beagle dogs following transdermal and intravenous administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26639828/),[ng] / [ml],2.09,39414,DB00871,Terbutaline
,26639828,Cmax,The Cmax was 2.09 ng/mL at 16.0 h for a 0.2 mg/kg patch and 4.85 ng/mL at 13.6 h for a 0.4 mg/kg patch.,"The pharmacokinetics of the β2-adrenoceptor agonist, tulobuterol, in Beagle dogs following transdermal and intravenous administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26639828/),[ng] / [ml],4.85,39415,DB00871,Terbutaline
,26639828,effective blood level,"The effective blood level in humans is 1-3 ng/mL, a concentration achieved using the 0.2 mg/kg patch in dogs.","The pharmacokinetics of the β2-adrenoceptor agonist, tulobuterol, in Beagle dogs following transdermal and intravenous administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26639828/),[ng] / [ml],1-3,39416,DB00871,Terbutaline
,17193884,peak serum concentration,"After i.v. administration of 0.5 mg/kg, the mean peak serum concentration, residence time, and half-life were 708.22 (standard deviation 509.6) ng/mL, 6.75 (3.6) min, and 6.93 (2.4) min, respectively.",Terbutaline pharmacokinetics in cows: preliminary data. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17193884/),[ng] / [ml],708.22,40780,DB00871,Terbutaline
,17193884,residence time,"After i.v. administration of 0.5 mg/kg, the mean peak serum concentration, residence time, and half-life were 708.22 (standard deviation 509.6) ng/mL, 6.75 (3.6) min, and 6.93 (2.4) min, respectively.",Terbutaline pharmacokinetics in cows: preliminary data. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17193884/),min,6.75,40781,DB00871,Terbutaline
,17193884,half-life,"After i.v. administration of 0.5 mg/kg, the mean peak serum concentration, residence time, and half-life were 708.22 (standard deviation 509.6) ng/mL, 6.75 (3.6) min, and 6.93 (2.4) min, respectively.",Terbutaline pharmacokinetics in cows: preliminary data. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17193884/),min,6.93,40782,DB00871,Terbutaline
,28072631,Maximum serum concentration of terbutaline (Cmax),"Maximum serum concentration of terbutaline (Cmax) (6.4 ± 1.2 vs 4.9 ± 1.2 ng·mL, P = 0.01) (mean ± 95% confidence interval) and area under serum concentration-time curve from 0 to 4 h after inhalation (AUC0-4) (16 ± 3 vs 13 ± 2 ng·mL·h, P ≤ 0.005) were higher after 7 d of inhalation compared with the first day.",Terbutaline Accumulates in Blood and Urine after Daily Therapeutic Inhalation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28072631/),ml·ng,6.4,41082,DB00871,Terbutaline
,28072631,Maximum serum concentration of terbutaline (Cmax),"Maximum serum concentration of terbutaline (Cmax) (6.4 ± 1.2 vs 4.9 ± 1.2 ng·mL, P = 0.01) (mean ± 95% confidence interval) and area under serum concentration-time curve from 0 to 4 h after inhalation (AUC0-4) (16 ± 3 vs 13 ± 2 ng·mL·h, P ≤ 0.005) were higher after 7 d of inhalation compared with the first day.",Terbutaline Accumulates in Blood and Urine after Daily Therapeutic Inhalation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28072631/),ml·ng,4.9,41083,DB00871,Terbutaline
,28072631,area under serum concentration-time curve from 0 to 4 h after inhalation (AUC0-4),"Maximum serum concentration of terbutaline (Cmax) (6.4 ± 1.2 vs 4.9 ± 1.2 ng·mL, P = 0.01) (mean ± 95% confidence interval) and area under serum concentration-time curve from 0 to 4 h after inhalation (AUC0-4) (16 ± 3 vs 13 ± 2 ng·mL·h, P ≤ 0.005) were higher after 7 d of inhalation compared with the first day.",Terbutaline Accumulates in Blood and Urine after Daily Therapeutic Inhalation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28072631/),h·ml·ng,16,41084,DB00871,Terbutaline
,28072631,area under serum concentration-time curve from 0 to 4 h after inhalation (AUC0-4),"Maximum serum concentration of terbutaline (Cmax) (6.4 ± 1.2 vs 4.9 ± 1.2 ng·mL, P = 0.01) (mean ± 95% confidence interval) and area under serum concentration-time curve from 0 to 4 h after inhalation (AUC0-4) (16 ± 3 vs 13 ± 2 ng·mL·h, P ≤ 0.005) were higher after 7 d of inhalation compared with the first day.",Terbutaline Accumulates in Blood and Urine after Daily Therapeutic Inhalation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28072631/),h·ml·ng,13,41085,DB00871,Terbutaline
,28072631,total urine excretion,"Seven days of terbutaline inhalation resulted in accumulation of terbutaline in urine, in which total urine excretion of terbutaline was higher after 7 d of inhalation compared with the first day (274 ± 43 vs 194 ± 33 μg, P ≤ 0.001).",Terbutaline Accumulates in Blood and Urine after Daily Therapeutic Inhalation. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28072631/),μg,274,41086,DB00871,Terbutaline
,28072631,total urine excretion,"Seven days of terbutaline inhalation resulted in accumulation of terbutaline in urine, in which total urine excretion of terbutaline was higher after 7 d of inhalation compared with the first day (274 ± 43 vs 194 ± 33 μg, P ≤ 0.001).",Terbutaline Accumulates in Blood and Urine after Daily Therapeutic Inhalation. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28072631/),μg,194,41087,DB00871,Terbutaline
,7697473,Cmax,"Cmax of tulobuterol was determined to be 1.33 +/- 0.21 ng/mL, Tmax was 14.0 +/- 2.0 hours, and AUCO-t was 27.1 +/- 4.2 ng.hr/mL.","Pharmacokinetics and pharmacodynamics of the tulobuterol patch, HN-078, in childhood asthma. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7697473/),[ng] / [ml],1.33,41821,DB00871,Terbutaline
,7697473,Tmax,"Cmax of tulobuterol was determined to be 1.33 +/- 0.21 ng/mL, Tmax was 14.0 +/- 2.0 hours, and AUCO-t was 27.1 +/- 4.2 ng.hr/mL.","Pharmacokinetics and pharmacodynamics of the tulobuterol patch, HN-078, in childhood asthma. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7697473/),h,14.0,41822,DB00871,Terbutaline
,7697473,AUCO-t,"Cmax of tulobuterol was determined to be 1.33 +/- 0.21 ng/mL, Tmax was 14.0 +/- 2.0 hours, and AUCO-t was 27.1 +/- 4.2 ng.hr/mL.","Pharmacokinetics and pharmacodynamics of the tulobuterol patch, HN-078, in childhood asthma. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7697473/),[h·ng] / [ml],27.1,41823,DB00871,Terbutaline
,11028225,Terminal half-life t1/2,"Terminal half-life t1/2 of the drug in blood with free drug solution was about 12 hr, whereas with liposomes, a twofold increase in t1/2 was observed.",Biodistribution of liposomes of terbutaline sulfate in guinea pigs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11028225/),h,12,62354,DB00871,Terbutaline
,6586483,constant rate,A condition approaching steady state seemed to be attained after infusion at a constant rate of 2.5 micrograms/min for 17-34 h with a mean plasma concentration of 6.7 micrograms/L.,Terbutaline in the treatment of preterm labour. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6586483/),[μg] / [min],2.5,66207,DB00871,Terbutaline
,6586483,total body clearance,This value would give a mean total body clearance of 0.30 L/min which is about one third higher than that previously found in healthy men.,Terbutaline in the treatment of preterm labour. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6586483/),[l] / [min],0.30,66208,DB00871,Terbutaline
,6586483,plasma concentrations,"The mean plasma concentrations of terbutaline during repeated tablet treatment were 3.4, 4.1 and 4.1 micrograms/L at 1, 2 and 4 h after administration, respectively.",Terbutaline in the treatment of preterm labour. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6586483/),[μg] / [l],3.4,66209,DB00871,Terbutaline
,6586483,plasma concentrations,"The mean plasma concentrations of terbutaline during repeated tablet treatment were 3.4, 4.1 and 4.1 micrograms/L at 1, 2 and 4 h after administration, respectively.",Terbutaline in the treatment of preterm labour. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6586483/),[μg] / [l],4.1,66210,DB00871,Terbutaline
,2991865,half-life,The long half-life previously reported in the literature (7 hours) is mainly the half-life of inactive fenoterol metabolites.,"Fenoterol: a beta2-adrenergic agonist for use in asthma. Pharmacology, pharmacokinetics, clinical efficacy and adverse effects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2991865/),h,7,66681,DB00871,Terbutaline
,24357101,flow rate,All samples were extracted with ethyl acetate and separated on a C₁₈ column under gradient elution with a mobile phase consisting of methanol and water containing 5 mm ammonium acetate at a flow rate of 0.6 mL/min.,A sensitive LC-MS/MS method for simultaneous determination of R-bambuterol and its active metabolite R-terbutaline in human plasma and urine with application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24357101/),[ml] / [min],0.6,69703,DB00871,Terbutaline
,18005375,in,"For theophylline, the concentration/time profiles after intraperitoneal and after intravenous administration were almost identical, and the intraperitoneal bioavailability was calculated to 0.94.","Pharmacokinetics of intraperitoneally instilled aminophylline, terbutaline and tobramycin in pigs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18005375/),,0.94,73530,DB00871,Terbutaline
,18005375,bioavailability,"Moreover, the intraperitoneal bioavailability was lower than for theophylline (0.71 and 0.65, respectively).","Pharmacokinetics of intraperitoneally instilled aminophylline, terbutaline and tobramycin in pigs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18005375/),,0.71,73531,DB00871,Terbutaline
,18005375,bioavailability,"Moreover, the intraperitoneal bioavailability was lower than for theophylline (0.71 and 0.65, respectively).","Pharmacokinetics of intraperitoneally instilled aminophylline, terbutaline and tobramycin in pigs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18005375/),,0.65,73532,DB00871,Terbutaline
,3956566,terminal half-life,There was a subsequent decrease in mean terminal half-life from 5.3 to 3.7 h and in mean residence time from 5.3 to 3.4 h.,Pharmacokinetics of terbutaline during pregnancy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3956566/),h,5,77026,DB00871,Terbutaline
,3956566,mean residence time,There was a subsequent decrease in mean terminal half-life from 5.3 to 3.7 h and in mean residence time from 5.3 to 3.4 h.,Pharmacokinetics of terbutaline during pregnancy. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3956566/),h,5.3,77027,DB00871,Terbutaline
,7199922,biological half-life,"Some important parameters are the biological half-life at 3.6 h (SD = 1.0), the body clearance at 0.26 l/(kg x h) (SD = 0.09), the volume of the reference compartment at 0.47 l/kg (SD = 0.10) and the volume in the steady state at 1.01 l/kg (SD = 0.14).","Pharmacokinetics of terbutaline, a beta 2-sympathomimetic, in healthy volunteers and asthmatic patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7199922/),h,3.6,79912,DB00871,Terbutaline
,7199922,body clearance,"Some important parameters are the biological half-life at 3.6 h (SD = 1.0), the body clearance at 0.26 l/(kg x h) (SD = 0.09), the volume of the reference compartment at 0.47 l/kg (SD = 0.10) and the volume in the steady state at 1.01 l/kg (SD = 0.14).","Pharmacokinetics of terbutaline, a beta 2-sympathomimetic, in healthy volunteers and asthmatic patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7199922/),[l] / [h·kg],0.26,79913,DB00871,Terbutaline
,7199922,volume of the reference compartment,"Some important parameters are the biological half-life at 3.6 h (SD = 1.0), the body clearance at 0.26 l/(kg x h) (SD = 0.09), the volume of the reference compartment at 0.47 l/kg (SD = 0.10) and the volume in the steady state at 1.01 l/kg (SD = 0.14).","Pharmacokinetics of terbutaline, a beta 2-sympathomimetic, in healthy volunteers and asthmatic patients. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7199922/),[l] / [kg],0.47,79914,DB00871,Terbutaline
,7199922,volume in the steady state,"Some important parameters are the biological half-life at 3.6 h (SD = 1.0), the body clearance at 0.26 l/(kg x h) (SD = 0.09), the volume of the reference compartment at 0.47 l/kg (SD = 0.10) and the volume in the steady state at 1.01 l/kg (SD = 0.14).","Pharmacokinetics of terbutaline, a beta 2-sympathomimetic, in healthy volunteers and asthmatic patients. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7199922/),[l] / [kg],1.01,79915,DB00871,Terbutaline
,7199922,absolute bioavailability,The absolute bioavailability is calculated at 10%.,"Pharmacokinetics of terbutaline, a beta 2-sympathomimetic, in healthy volunteers and asthmatic patients. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7199922/),%,10,79916,DB00871,Terbutaline
,1848636,IC50,"There was a difference in metoprolol potency with higher racemic metoprolol IC50 values in PMs (72 +/- 7 ng.ml-1) than EMs (42 +/- 8 ng.ml-1, P less than .001).",Debrisoquine phenotype and the pharmacokinetics and beta-2 receptor pharmacodynamics of metoprolol and its enantiomers. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1848636/),[ng] / [ml],72,82447,DB00871,Terbutaline
,1848636,IC50,"There was a difference in metoprolol potency with higher racemic metoprolol IC50 values in PMs (72 +/- 7 ng.ml-1) than EMs (42 +/- 8 ng.ml-1, P less than .001).",Debrisoquine phenotype and the pharmacokinetics and beta-2 receptor pharmacodynamics of metoprolol and its enantiomers. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1848636/),[ng] / [ml],42,82448,DB00871,Terbutaline
,2038728,time to peak terbutaline concentration,"The plasma concentration of terbutaline rose much faster in smokers than in non-smokers, the mean time to peak terbutaline concentration being 17 minutes in the smokers and 50 minutes in the non-smokers.",Difference in pulmonary absorption of inhaled terbutaline in healthy smokers and non-smokers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038728/),min,17,83611,DB00871,Terbutaline
,2038728,time to peak terbutaline concentration,"The plasma concentration of terbutaline rose much faster in smokers than in non-smokers, the mean time to peak terbutaline concentration being 17 minutes in the smokers and 50 minutes in the non-smokers.",Difference in pulmonary absorption of inhaled terbutaline in healthy smokers and non-smokers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038728/),min,50,83612,DB00871,Terbutaline
,2038728,peak plasma concentration,"The peak plasma concentration was nearly twice as high in the smokers as in the non-smokers, being 21 mmol/l and 23 mmol/l for the dry powder inhalation and nebuliser respectively in the smokers and 12 mmol/l and 14 mmol/l in the non-smokers.",Difference in pulmonary absorption of inhaled terbutaline in healthy smokers and non-smokers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038728/),[mM] / [l],21,83613,DB00871,Terbutaline
,2038728,peak plasma concentration,"The peak plasma concentration was nearly twice as high in the smokers as in the non-smokers, being 21 mmol/l and 23 mmol/l for the dry powder inhalation and nebuliser respectively in the smokers and 12 mmol/l and 14 mmol/l in the non-smokers.",Difference in pulmonary absorption of inhaled terbutaline in healthy smokers and non-smokers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038728/),[mM] / [l],23,83614,DB00871,Terbutaline
,2038728,peak plasma concentration,"The peak plasma concentration was nearly twice as high in the smokers as in the non-smokers, being 21 mmol/l and 23 mmol/l for the dry powder inhalation and nebuliser respectively in the smokers and 12 mmol/l and 14 mmol/l in the non-smokers.",Difference in pulmonary absorption of inhaled terbutaline in healthy smokers and non-smokers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038728/),[mM] / [l],12,83615,DB00871,Terbutaline
,2038728,peak plasma concentration,"The peak plasma concentration was nearly twice as high in the smokers as in the non-smokers, being 21 mmol/l and 23 mmol/l for the dry powder inhalation and nebuliser respectively in the smokers and 12 mmol/l and 14 mmol/l in the non-smokers.",Difference in pulmonary absorption of inhaled terbutaline in healthy smokers and non-smokers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038728/),[mM] / [l],14,83616,DB00871,Terbutaline
,21495261,total flow rate,Perfusion experiments were conducted using Krebs bicarbonate buffer delivered via the portal vein in a single-pass mode at a total flow rate of 15 mL min(-1).,Investigation of distribution and elimination of terbutaline sulfate in the perfused rat liver preparation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21495261/),[ml] / [min],15,87950,DB00871,Terbutaline
,21495261,protein binding,"Although protein binding of TBS was very low (2.5%), it was taken up slowly and continuously by erythrocytes.",Investigation of distribution and elimination of terbutaline sulfate in the perfused rat liver preparation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21495261/),%,2.5,87951,DB00871,Terbutaline
,21495261,blood to plasma concentration ratio,A blood to plasma concentration ratio of 2.8 obtained at the end of incubation period clearly indicates that TBS has an affinity to erythrocytes.,Investigation of distribution and elimination of terbutaline sulfate in the perfused rat liver preparation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21495261/),,2.8,87952,DB00871,Terbutaline
,2888791,clearance,"Pretreatment with four days of terbutaline (5 mg q8h) and propranolol (60 mg q8h) significantly decreased mean theophylline clearance (60.1 +/- 12.9 vs 40.6 +/- 9.9 mL/min/1.73m2; P less than .01) increased half-life (8.37 +/- 1.77 vs 12.32 +/- 2.70 hours; P less than .05), and increased postinfusion theophylline concentration (13.5 +/- 2.7 vs 18.95 +/- 2.5 micrograms/mL; P less than .001).",The effects of a beta-2 selective adrenergic agonist and a beta-nonselective antagonist on theophylline clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888791/),[ml] / [1.73m2·min],60.1,88065,DB00871,Terbutaline
,2888791,clearance,"Pretreatment with four days of terbutaline (5 mg q8h) and propranolol (60 mg q8h) significantly decreased mean theophylline clearance (60.1 +/- 12.9 vs 40.6 +/- 9.9 mL/min/1.73m2; P less than .01) increased half-life (8.37 +/- 1.77 vs 12.32 +/- 2.70 hours; P less than .05), and increased postinfusion theophylline concentration (13.5 +/- 2.7 vs 18.95 +/- 2.5 micrograms/mL; P less than .001).",The effects of a beta-2 selective adrenergic agonist and a beta-nonselective antagonist on theophylline clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888791/),[ml] / [1.73m2·min],40.6,88066,DB00871,Terbutaline
,2888791,half-life,"Pretreatment with four days of terbutaline (5 mg q8h) and propranolol (60 mg q8h) significantly decreased mean theophylline clearance (60.1 +/- 12.9 vs 40.6 +/- 9.9 mL/min/1.73m2; P less than .01) increased half-life (8.37 +/- 1.77 vs 12.32 +/- 2.70 hours; P less than .05), and increased postinfusion theophylline concentration (13.5 +/- 2.7 vs 18.95 +/- 2.5 micrograms/mL; P less than .001).",The effects of a beta-2 selective adrenergic agonist and a beta-nonselective antagonist on theophylline clearance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888791/),h,8.37,88067,DB00871,Terbutaline
,2888791,half-life,"Pretreatment with four days of terbutaline (5 mg q8h) and propranolol (60 mg q8h) significantly decreased mean theophylline clearance (60.1 +/- 12.9 vs 40.6 +/- 9.9 mL/min/1.73m2; P less than .01) increased half-life (8.37 +/- 1.77 vs 12.32 +/- 2.70 hours; P less than .05), and increased postinfusion theophylline concentration (13.5 +/- 2.7 vs 18.95 +/- 2.5 micrograms/mL; P less than .001).",The effects of a beta-2 selective adrenergic agonist and a beta-nonselective antagonist on theophylline clearance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888791/),h,12.32,88068,DB00871,Terbutaline
,2888791,clearance,In five subjects theophylline clearance increased after terbutaline pretreatment (64.6 +/- 13.0 vs 75.0 +/- 13.9 mL/min/1.73m2).,The effects of a beta-2 selective adrenergic agonist and a beta-nonselective antagonist on theophylline clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888791/),[ml] / [1.73m2·min],64.6,88069,DB00871,Terbutaline
,2888791,clearance,In five subjects theophylline clearance increased after terbutaline pretreatment (64.6 +/- 13.0 vs 75.0 +/- 13.9 mL/min/1.73m2).,The effects of a beta-2 selective adrenergic agonist and a beta-nonselective antagonist on theophylline clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888791/),[ml] / [1.73m2·min],75.0,88070,DB00871,Terbutaline
,2888791,clearance,Comparison between the propranolol and terbutaline study and the propranolol alone study indicated no mean change in clearance in these five subjects (41.8 +/- 12.7 vs 36.1 +/- 5.1 mL/min/1.73m2).,The effects of a beta-2 selective adrenergic agonist and a beta-nonselective antagonist on theophylline clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888791/),[ml] / [1.73m2·min],41.8,88071,DB00871,Terbutaline
,2888791,clearance,Comparison between the propranolol and terbutaline study and the propranolol alone study indicated no mean change in clearance in these five subjects (41.8 +/- 12.7 vs 36.1 +/- 5.1 mL/min/1.73m2).,The effects of a beta-2 selective adrenergic agonist and a beta-nonselective antagonist on theophylline clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888791/),[ml] / [1.73m2·min],36.1,88072,DB00871,Terbutaline
,9643621,terminal half-life,"However, subjects with atypical cholinesterase had a shorter terminal half-life of bambuterol (a measure of uptake rate), 4.8-12.6 h vs 8.3-22.3 h in N, and slightly higher plasma concentrations of bambuterol (average concentrations 1.9-3.7 nmol l(-1) vs 1.5-3.1 nmol l(-1) in N).",Pharmacokinetics of bambuterol in subjects homozygous for the atypical gene for plasma cholinesterase. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9643621/),h,4.8-12.6,88509,DB00871,Terbutaline
,9643621,terminal half-life,"However, subjects with atypical cholinesterase had a shorter terminal half-life of bambuterol (a measure of uptake rate), 4.8-12.6 h vs 8.3-22.3 h in N, and slightly higher plasma concentrations of bambuterol (average concentrations 1.9-3.7 nmol l(-1) vs 1.5-3.1 nmol l(-1) in N).",Pharmacokinetics of bambuterol in subjects homozygous for the atypical gene for plasma cholinesterase. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9643621/),h,8.3-22.3,88510,DB00871,Terbutaline
,9643621,Peak/trough terbutaline plasma concentrations ratios,"Peak/trough terbutaline plasma concentrations ratios (2.1-3.2) were somewhat increased, but average plasma concentrations (8.3-14.5 nmol l(-1)) and terminal half-life (16.5-21.8 h) of terbutaline did not differ.",Pharmacokinetics of bambuterol in subjects homozygous for the atypical gene for plasma cholinesterase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9643621/),,2.1-3.2,88511,DB00871,Terbutaline
,9643621,terminal half-life,"Peak/trough terbutaline plasma concentrations ratios (2.1-3.2) were somewhat increased, but average plasma concentrations (8.3-14.5 nmol l(-1)) and terminal half-life (16.5-21.8 h) of terbutaline did not differ.",Pharmacokinetics of bambuterol in subjects homozygous for the atypical gene for plasma cholinesterase. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9643621/),h,16.5-21.8,88512,DB00871,Terbutaline
,2917584,serum trough,"Terbutaline decreased the serum trough theophylline levels from 8.1 to 7.3 micrograms/ml, improved daily the clinical score from 1.51 to 1.26 and increased the peak expiratory flow rate from 316 to 370 l/min.",Increased theophylline clearance in asthmatic patients due to terbutaline. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2917584/),[μg] / [ml],8.1 to 7.3,91160,DB00871,Terbutaline
,2917584,peak expiratory flow rate,"Terbutaline decreased the serum trough theophylline levels from 8.1 to 7.3 micrograms/ml, improved daily the clinical score from 1.51 to 1.26 and increased the peak expiratory flow rate from 316 to 370 l/min.",Increased theophylline clearance in asthmatic patients due to terbutaline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2917584/),[l] / [min],316,91161,DB00871,Terbutaline
,2917584,peak expiratory flow rate,"Terbutaline decreased the serum trough theophylline levels from 8.1 to 7.3 micrograms/ml, improved daily the clinical score from 1.51 to 1.26 and increased the peak expiratory flow rate from 316 to 370 l/min.",Increased theophylline clearance in asthmatic patients due to terbutaline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2917584/),[l] / [min],370,91162,DB00871,Terbutaline
,2917584,t1/2,"In a single dose study following the chronic therapy, it was shown that there was no change in the peak theophylline concentration or in the timing of the peak, but the t1/2 was reduced from 9.0 to 7.5 h, and the systemic clearance was increased from 20.2 to 24.8 ml.h-1.kg-1.",Increased theophylline clearance in asthmatic patients due to terbutaline. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2917584/),h,9,91163,DB00871,Terbutaline
,2917584,t1/2,"In a single dose study following the chronic therapy, it was shown that there was no change in the peak theophylline concentration or in the timing of the peak, but the t1/2 was reduced from 9.0 to 7.5 h, and the systemic clearance was increased from 20.2 to 24.8 ml.h-1.kg-1.",Increased theophylline clearance in asthmatic patients due to terbutaline. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2917584/),h,7,91164,DB00871,Terbutaline
,2917584,systemic clearance,"In a single dose study following the chronic therapy, it was shown that there was no change in the peak theophylline concentration or in the timing of the peak, but the t1/2 was reduced from 9.0 to 7.5 h, and the systemic clearance was increased from 20.2 to 24.8 ml.h-1.kg-1.",Increased theophylline clearance in asthmatic patients due to terbutaline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2917584/),[ml] / [h·kg],20.2,91165,DB00871,Terbutaline
,12852442,absorption half-life,"The absorption half-life of the investigated drugs ranged from 2 to 59 min, and the extent of absorption from 21 to 94% in 2 h in the isolated perfused rat lung model.",Drug absorption from the isolated perfused rat lung--correlations with drug physicochemical properties and epithelial permeability. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12852442/),min,2 to 59,102577,DB00871,Terbutaline
,12580109,flow-rate,"The mobile phase consisted of acetonitrile-water-formic acid (20:80:1), at a flow-rate of 0.4 mL.min-1.",[Rapid analysis of terbutaline by combined solid phase extraction/liquid chromatography tandem mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12580109/),[ml] / [min],0.4,112113,DB00871,Terbutaline
,12580109,ch,The chromatographic analysis time for each sample was approximately 3.8 min.,[Rapid analysis of terbutaline by combined solid phase extraction/liquid chromatography tandem mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12580109/),min,3.8,112114,DB00871,Terbutaline
,6586475,terminal half-life,Prolonged sampling reveals that the terminal half-life of terbutaline in healthy subjects is about 17 h with an about twofold variation between subjects.,Pharmacokinetic parameters of terbutaline in healthy man. An overview. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6586475/),h,17,118641,DB00871,Terbutaline
,6586475,body clearance,"On average, they have a body clearance of 3.0 mL/min/kg, 2/3 of this being the renal contribution.",Pharmacokinetic parameters of terbutaline in healthy man. An overview. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6586475/),[ml] / [kg·min],3.0,118642,DB00871,Terbutaline
,6586475,volume of distribution at steady state,Terbutaline's volume of distribution at steady state averages 1.6 L/kg.,Pharmacokinetic parameters of terbutaline in healthy man. An overview. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6586475/),[l] / [kg],1.6,118643,DB00871,Terbutaline
,6586475,systemic mean residence time,The systemic mean residence time of the drug is about 9 h.,Pharmacokinetic parameters of terbutaline in healthy man. An overview. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6586475/),h,9,118644,DB00871,Terbutaline
,6586475,bioavailability,"This creates a range in the extent of bioavailability of 7-26%, the decrease of the percentages being due to a high first-pass metabolism.",Pharmacokinetic parameters of terbutaline in healthy man. An overview. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6586475/),%,7-26,118645,DB00871,Terbutaline
,6586475,bioavailability,Mean bioavailability of oral terbutaline in fasting subjects is 14-15%.,Pharmacokinetic parameters of terbutaline in healthy man. An overview. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6586475/),%,14-15,118646,DB00871,Terbutaline
,12579977,Tmax,After an oral administration of 10 mg bambuterol hydrochloride to 18 healthy Chinese volunteers the main pharmacokinetic parameters of bambuterol were as follows: Tmax was (2.3 +/- 1.3) h; Cmax was (3.95 +/- 2.20) ng.mL-1; T1/2 was (11.4 +/- 6.1) h and AUC0-t was (26.85 +/- 11.77) ng.h.mL-1.,[Determination of bambuterol in human plasma by liquid chromatography-electrospray tandem mass spectrometry: application to pharmacokinetic study]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12579977/),h,2.3,120542,DB00871,Terbutaline
,12579977,Cmax,After an oral administration of 10 mg bambuterol hydrochloride to 18 healthy Chinese volunteers the main pharmacokinetic parameters of bambuterol were as follows: Tmax was (2.3 +/- 1.3) h; Cmax was (3.95 +/- 2.20) ng.mL-1; T1/2 was (11.4 +/- 6.1) h and AUC0-t was (26.85 +/- 11.77) ng.h.mL-1.,[Determination of bambuterol in human plasma by liquid chromatography-electrospray tandem mass spectrometry: application to pharmacokinetic study]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12579977/),[ng] / [ml],3.95,120543,DB00871,Terbutaline
,12579977,T1/2,After an oral administration of 10 mg bambuterol hydrochloride to 18 healthy Chinese volunteers the main pharmacokinetic parameters of bambuterol were as follows: Tmax was (2.3 +/- 1.3) h; Cmax was (3.95 +/- 2.20) ng.mL-1; T1/2 was (11.4 +/- 6.1) h and AUC0-t was (26.85 +/- 11.77) ng.h.mL-1.,[Determination of bambuterol in human plasma by liquid chromatography-electrospray tandem mass spectrometry: application to pharmacokinetic study]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12579977/),h,11.4,120544,DB00871,Terbutaline
,12579977,AUC0-t,After an oral administration of 10 mg bambuterol hydrochloride to 18 healthy Chinese volunteers the main pharmacokinetic parameters of bambuterol were as follows: Tmax was (2.3 +/- 1.3) h; Cmax was (3.95 +/- 2.20) ng.mL-1; T1/2 was (11.4 +/- 6.1) h and AUC0-t was (26.85 +/- 11.77) ng.h.mL-1.,[Determination of bambuterol in human plasma by liquid chromatography-electrospray tandem mass spectrometry: application to pharmacokinetic study]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12579977/),[h·ng] / [ml],26.85,120545,DB00871,Terbutaline
,6586482,steady-state concentrations,"On 3 separate days, theophylline was infused to defined steady-state concentrations (0, 7.5, and 15 micrograms/mL, respectively) followed by the administration, at intervals of 1 h, of incremental intravenous doses of terbutaline.",Simultaneous treatment with terbutaline and theophylline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6586482/),[μg] / [ml],0,121685,DB00871,Terbutaline
,6586482,steady-state concentrations,"On 3 separate days, theophylline was infused to defined steady-state concentrations (0, 7.5, and 15 micrograms/mL, respectively) followed by the administration, at intervals of 1 h, of incremental intravenous doses of terbutaline.",Simultaneous treatment with terbutaline and theophylline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6586482/),[μg] / [ml],7.5,121686,DB00871,Terbutaline
,6586482,steady-state concentrations,"On 3 separate days, theophylline was infused to defined steady-state concentrations (0, 7.5, and 15 micrograms/mL, respectively) followed by the administration, at intervals of 1 h, of incremental intravenous doses of terbutaline.",Simultaneous treatment with terbutaline and theophylline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6586482/),[μg] / [ml],15,121687,DB00871,Terbutaline
,6586482,steady-state concentration,"At the highest steady-state concentration (15 micrograms/mL), 2 of the patients experienced nausea.",Simultaneous treatment with terbutaline and theophylline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6586482/),[μg] / [ml],15,121688,DB00871,Terbutaline
,6586480,terminal half-life,The terminal half-life ranged from 8.8 to 15.8 (mean 12.1) h.,Kinetics of terbutaline in asthmatic children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6586480/),h,12.1,130284,DB00871,Terbutaline
,6586480,Body clearance,"Body clearance (mean +/- SD) was 3.76 +/- 0.86, renal clearance 2.42 +/- 0.49 mL/min/kg.",Kinetics of terbutaline in asthmatic children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6586480/),,3.76,130285,DB00871,Terbutaline
,6586480,renal clearance,"Body clearance (mean +/- SD) was 3.76 +/- 0.86, renal clearance 2.42 +/- 0.49 mL/min/kg.",Kinetics of terbutaline in asthmatic children. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6586480/),[ml] / [kg·min],2.42,130286,DB00871,Terbutaline
,6586480,volume of distribution at steady state,The volume of distribution at steady state was 1.57 +/- 0.19 L/kg.,Kinetics of terbutaline in asthmatic children. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6586480/),[l] / [kg],1.57,130287,DB00871,Terbutaline
,6586480,total recovery,The extrapolated recovery of intact terbutaline in urine was 65.4 +/- 6.5% of the dose and the total recovery 80.8 +/- 8.4%.,Kinetics of terbutaline in asthmatic children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6586480/),%,80.8,130288,DB00871,Terbutaline
,6586480,recovery,"After oral administration, the recovery of intact terbutaline in urine was 6.2 +/- 1.1%.",Kinetics of terbutaline in asthmatic children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6586480/),%,6.2,130289,DB00871,Terbutaline
,6586480,Absorption,"Absorption was on average 33%, but because of a mean first-pass elimination of 70%, bioavailability was 9.5 +/- 2.4%.",Kinetics of terbutaline in asthmatic children. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6586480/),%,33,130290,DB00871,Terbutaline
,6586480,bioavailability,"Absorption was on average 33%, but because of a mean first-pass elimination of 70%, bioavailability was 9.5 +/- 2.4%.",Kinetics of terbutaline in asthmatic children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6586480/),%,9.5,130291,DB00871,Terbutaline
,15040091,AUC0-1,The pharmacokinetic parameters of the capsule and tablet of bambuterol: AUC0-1 were (72 +/- 18) and (72 +/- 13) microgram.,[Study on bioequivalence of domestic bambuterol capsules and imported tablets by high performance capillary zone electrophoresis]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15040091/),μg,72,132846,DB00871,Terbutaline
,15040091,AUC0-1,The pharmacokinetic parameters of the capsule and tablet of bambuterol: AUC0-1 were (72 +/- 18) and (72 +/- 13) microgram.,[Study on bioequivalence of domestic bambuterol capsules and imported tablets by high performance capillary zone electrophoresis]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15040091/),μg,72,132847,DB00871,Terbutaline
,15040091,Cmax,"h.L-1, Cmax were (8.1 +/- 1.8) and (9.2 +/- 2.3) microgram.",[Study on bioequivalence of domestic bambuterol capsules and imported tablets by high performance capillary zone electrophoresis]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15040091/),μg,8.1,132848,DB00871,Terbutaline
,15040091,Cmax,"h.L-1, Cmax were (8.1 +/- 1.8) and (9.2 +/- 2.3) microgram.",[Study on bioequivalence of domestic bambuterol capsules and imported tablets by high performance capillary zone electrophoresis]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15040091/),μg,9.2,132849,DB00871,Terbutaline
,15040091,Tmax,"L-1, Tmax were (3.6 +/- 1.3) and (3.7 +/- 1.0) h, respectively; terbutaline: AUC0-t were (129 +/- 32) and (130 +/- 34) microgram.",[Study on bioequivalence of domestic bambuterol capsules and imported tablets by high performance capillary zone electrophoresis]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15040091/),h,3.6,132850,DB00871,Terbutaline
,15040091,Tmax,"L-1, Tmax were (3.6 +/- 1.3) and (3.7 +/- 1.0) h, respectively; terbutaline: AUC0-t were (129 +/- 32) and (130 +/- 34) microgram.",[Study on bioequivalence of domestic bambuterol capsules and imported tablets by high performance capillary zone electrophoresis]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15040091/),h,3.7,132851,DB00871,Terbutaline
,15040091,AUC0-t,"L-1, Tmax were (3.6 +/- 1.3) and (3.7 +/- 1.0) h, respectively; terbutaline: AUC0-t were (129 +/- 32) and (130 +/- 34) microgram.",[Study on bioequivalence of domestic bambuterol capsules and imported tablets by high performance capillary zone electrophoresis]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15040091/),μg,129,132852,DB00871,Terbutaline
,15040091,AUC0-t,"L-1, Tmax were (3.6 +/- 1.3) and (3.7 +/- 1.0) h, respectively; terbutaline: AUC0-t were (129 +/- 32) and (130 +/- 34) microgram.",[Study on bioequivalence of domestic bambuterol capsules and imported tablets by high performance capillary zone electrophoresis]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15040091/),μg,130,132853,DB00871,Terbutaline
,15040091,Cmax,"h.L-1, Cmax were (7.8 +/- 2.2) and (8.5 +/- 2.9) microgram.",[Study on bioequivalence of domestic bambuterol capsules and imported tablets by high performance capillary zone electrophoresis]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15040091/),μg,7.8,132854,DB00871,Terbutaline
,15040091,Cmax,"h.L-1, Cmax were (7.8 +/- 2.2) and (8.5 +/- 2.9) microgram.",[Study on bioequivalence of domestic bambuterol capsules and imported tablets by high performance capillary zone electrophoresis]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15040091/),μg,8.5,132855,DB00871,Terbutaline
,15040091,Tmax,"L-1, Tmax were (5.4 +/- 0.8) and (5.6 +/- 1.1) h, respectively.",[Study on bioequivalence of domestic bambuterol capsules and imported tablets by high performance capillary zone electrophoresis]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15040091/),h,5.4,132856,DB00871,Terbutaline
,15040091,Tmax,"L-1, Tmax were (5.4 +/- 0.8) and (5.6 +/- 1.1) h, respectively.",[Study on bioequivalence of domestic bambuterol capsules and imported tablets by high performance capillary zone electrophoresis]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15040091/),h,5.6,132857,DB00871,Terbutaline
,15040091,bioavaiability,The bioavaiability of the capsule was (100 +/- 16)% (bambuterol) and (101 +/- 13)% (terbutaline).,[Study on bioequivalence of domestic bambuterol capsules and imported tablets by high performance capillary zone electrophoresis]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15040091/),%,100,132858,DB00871,Terbutaline
,15040091,bioavaiability,The bioavaiability of the capsule was (100 +/- 16)% (bambuterol) and (101 +/- 13)% (terbutaline).,[Study on bioequivalence of domestic bambuterol capsules and imported tablets by high performance capillary zone electrophoresis]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15040091/),%,101,132859,DB00871,Terbutaline
,26638035,runtime,"Plasma samples were extracted by liquid-liquid extraction method with methyl tert-butyl ether and the analyte and clenbuterol (IS) were separated on a Venusil MP C18 column (100mm×2.1mm, 3μm) using 0.1% formic acid-water-methanol as mobile phase, with a runtime of 5min.",Determination of tulobuterol in rat plasma using a liquid chromatography-tandem mass spectrometry method and its application to a pharmacokinetic study of tulobuterol patch. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26638035/),min,5,140354,DB00871,Terbutaline
,26638035,m/z,Transitions of m/z 228.2→154.0 for tulobuterol and m/z 277.1→203.0 for the clenbuterol were monitored.,Determination of tulobuterol in rat plasma using a liquid chromatography-tandem mass spectrometry method and its application to a pharmacokinetic study of tulobuterol patch. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26638035/),,228.2,140355,DB00871,Terbutaline
,26638035,m/z,Transitions of m/z 228.2→154.0 for tulobuterol and m/z 277.1→203.0 for the clenbuterol were monitored.,Determination of tulobuterol in rat plasma using a liquid chromatography-tandem mass spectrometry method and its application to a pharmacokinetic study of tulobuterol patch. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26638035/),,154.0,140356,DB00871,Terbutaline
,26638035,m/z,Transitions of m/z 228.2→154.0 for tulobuterol and m/z 277.1→203.0 for the clenbuterol were monitored.,Determination of tulobuterol in rat plasma using a liquid chromatography-tandem mass spectrometry method and its application to a pharmacokinetic study of tulobuterol patch. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26638035/),,277.1,140357,DB00871,Terbutaline
,26638035,m/z,Transitions of m/z 228.2→154.0 for tulobuterol and m/z 277.1→203.0 for the clenbuterol were monitored.,Determination of tulobuterol in rat plasma using a liquid chromatography-tandem mass spectrometry method and its application to a pharmacokinetic study of tulobuterol patch. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26638035/),,203.0,140358,DB00871,Terbutaline
,1526088,area under the concentration versus time curve,"There was a greater area under the concentration versus time curve for terbutaline during a dose interval in older patients compared with younger patients (558 +/- 171 and 376 +/- 149 nmol.hr/L, respectively [mean +/- SD], p less than 0.021).","Pharmacokinetics and pharmacodynamics of bambuterol, a long-acting bronchodilator pro-drug of terbutaline, in young and elderly patients with asthma. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1526088/),[h·nM] / [l],558,140466,DB00871,Terbutaline
,1526088,area under the concentration versus time curve,"There was a greater area under the concentration versus time curve for terbutaline during a dose interval in older patients compared with younger patients (558 +/- 171 and 376 +/- 149 nmol.hr/L, respectively [mean +/- SD], p less than 0.021).","Pharmacokinetics and pharmacodynamics of bambuterol, a long-acting bronchodilator pro-drug of terbutaline, in young and elderly patients with asthma. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1526088/),[h·nM] / [l],376,140467,DB00871,Terbutaline
,1526088,apparent plasma terbutaline clearance,"This was reflected in a lower apparent plasma terbutaline clearance in older patients compared with younger patients (1.22 +/- 0.33 and 2.32 +/- 1.26 L/hr/kg, respectively, p less than 0.023).","Pharmacokinetics and pharmacodynamics of bambuterol, a long-acting bronchodilator pro-drug of terbutaline, in young and elderly patients with asthma. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1526088/),[l] / [h·kg],1.22,140468,DB00871,Terbutaline
,1526088,apparent plasma terbutaline clearance,"This was reflected in a lower apparent plasma terbutaline clearance in older patients compared with younger patients (1.22 +/- 0.33 and 2.32 +/- 1.26 L/hr/kg, respectively, p less than 0.023).","Pharmacokinetics and pharmacodynamics of bambuterol, a long-acting bronchodilator pro-drug of terbutaline, in young and elderly patients with asthma. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1526088/),[l] / [h·kg],2.32,140469,DB00871,Terbutaline
,12175748,time required for complete degradation,"In the absence of trypsin, the time required for complete degradation of microspheres was increased from 144 to 264 h when the glutaraldehyde concentration increased from 0.1 to 0.7 ml.","Preparation, characterization and in vivo distribution of terbutaline sulfate loaded albumin microspheres. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12175748/),h,144,145111,DB00871,Terbutaline
,12175748,time required for complete degradation,"In the absence of trypsin, the time required for complete degradation of microspheres was increased from 144 to 264 h when the glutaraldehyde concentration increased from 0.1 to 0.7 ml.","Preparation, characterization and in vivo distribution of terbutaline sulfate loaded albumin microspheres. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12175748/),h,264,145112,DB00871,Terbutaline
,27375484,Cmax,"Serum Cmax and area under the serum concentration-time curve (AUC) were lower after oral administration compared to inhalation (Cmax: 4.2 ± 0.3 vs. 8.5 ± 0.7 ng/ml, P ≤ 0.001; AUC: 422 ± 22 vs. 1308 ± 119 ng/ml × min).",Pharmacokinetics of Oral and Inhaled Terbutaline after Exercise in Trained Men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27375484/),[ng] / [ml],4.2,153707,DB00871,Terbutaline
,27375484,Cmax,"Serum Cmax and area under the serum concentration-time curve (AUC) were lower after oral administration compared to inhalation (Cmax: 4.2 ± 0.3 vs. 8.5 ± 0.7 ng/ml, P ≤ 0.001; AUC: 422 ± 22 vs. 1308 ± 119 ng/ml × min).",Pharmacokinetics of Oral and Inhaled Terbutaline after Exercise in Trained Men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27375484/),[ng] / [ml],8.5,153708,DB00871,Terbutaline
,27375484,AUC,"Serum Cmax and area under the serum concentration-time curve (AUC) were lower after oral administration compared to inhalation (Cmax: 4.2 ± 0.3 vs. 8.5 ± 0.7 ng/ml, P ≤ 0.001; AUC: 422 ± 22 vs. 1308 ± 119 ng/ml × min).",Pharmacokinetics of Oral and Inhaled Terbutaline after Exercise in Trained Men. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27375484/),[ng] / [min·ml],422,153709,DB00871,Terbutaline
,27375484,AUC,"Serum Cmax and area under the serum concentration-time curve (AUC) were lower after oral administration compared to inhalation (Cmax: 4.2 ± 0.3 vs. 8.5 ± 0.7 ng/ml, P ≤ 0.001; AUC: 422 ± 22 vs. 1308 ± 119 ng/ml × min).",Pharmacokinetics of Oral and Inhaled Terbutaline after Exercise in Trained Men. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27375484/),[ng] / [min·ml],1308,153710,DB00871,Terbutaline
,27375484,Systemic bioavailability ratio,Systemic bioavailability ratio between the two routes of administration was 3.8:1 (inhaled: oral; P ≤ 0.001).,Pharmacokinetics of Oral and Inhaled Terbutaline after Exercise in Trained Men. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27375484/),:1,3.8,153711,DB00871,Terbutaline
,6586488,uptake half-time,"Assuming a monoexponential uptake and a final ratio in vitro similar to that in vivo (about 2.3), we would estimate an uptake half-time between 3.5 and 8.5 h.",Pharmacokinetic implications of slow equilibration of terbutaline between plasma and erythrocytes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6586488/),h,3.5 and 8.5,154637,DB00871,Terbutaline
,8099880,tmax,"Tulobuterol was rapidly absorbed after inhalation, with a tmax of 0.8-1.5 h.","The pharmacokinetics of the beta 2-adrenoceptor agonist, tulobuterol, given transdermally and by inhalation. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8099880/),h,0.8-1.5,157225,DB00871,Terbutaline
,8099880,absorption lag-time,"Tulobuterol was well absorbed after transdermal administration, with an absorption lag-time of about 4 h.","The pharmacokinetics of the beta 2-adrenoceptor agonist, tulobuterol, given transdermally and by inhalation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8099880/),h,4,157226,DB00871,Terbutaline
,8099880,tmax,The Cmax and AUC increased linearly with dose and the tmax was about 9-12 h.,"The pharmacokinetics of the beta 2-adrenoceptor agonist, tulobuterol, given transdermally and by inhalation. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8099880/),h,9-12,157227,DB00871,Terbutaline
,8099880,percentage of drug absorbed,The mean percentage of drug absorbed during the application of a patch for 24 h was 82-90% after a single dose and 82-85% during repeated dosing.,"The pharmacokinetics of the beta 2-adrenoceptor agonist, tulobuterol, given transdermally and by inhalation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8099880/),%,82-90,157228,DB00871,Terbutaline
,8099880,percentage of drug absorbed,The mean percentage of drug absorbed during the application of a patch for 24 h was 82-90% after a single dose and 82-85% during repeated dosing.,"The pharmacokinetics of the beta 2-adrenoceptor agonist, tulobuterol, given transdermally and by inhalation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8099880/),%,82-85,157229,DB00871,Terbutaline
,8099880,urinary recoveries,The mean urinary recoveries as unchanged drug after a single inhalation and patch application were 3-4% and 5-6% respectively.,"The pharmacokinetics of the beta 2-adrenoceptor agonist, tulobuterol, given transdermally and by inhalation. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8099880/),%,3-4,157230,DB00871,Terbutaline
,8099880,urinary recoveries,The mean urinary recoveries as unchanged drug after a single inhalation and patch application were 3-4% and 5-6% respectively.,"The pharmacokinetics of the beta 2-adrenoceptor agonist, tulobuterol, given transdermally and by inhalation. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8099880/),%,5-6,157231,DB00871,Terbutaline
,2322639,Maximal plasma concentration,"Maximal plasma concentration, 8.7 (range: 4.9-15.2) nmol l-1, was reached after 4.7 (2.2-6.0) h.",Absolute bioavailability of terbutaline from a CR-granulate in asthmatic children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2322639/),[nM] / [l],8.7,157425,DB00871,Terbutaline
,2322639,Absolute bioavailability,Absolute bioavailability was 10.8 (7.63-16.4) per cent.,Absolute bioavailability of terbutaline from a CR-granulate in asthmatic children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2322639/),%,10.8,157426,DB00871,Terbutaline
,20096531,flow-rate,"All analytes and the internal standard were extracted from rat plasma samples by liquid-liquid extraction, separated on macrocyclic glycopeptide teicoplanin column with mobile phase constituted of 20mM ammonium acetate solution-methanol (10:90, v/v) at a flow-rate of 0.4 mL/min.",Simultaneous analysis of bambuterol and its active metabolite terbutaline enantiomers in rat plasma by chiral liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20096531/),[ml] / [min],0.4,157457,DB00871,Terbutaline
,10510139,AUC,"Mean AUC of terbutaline was 128 and 242 nmol l-1 h in the preschool Caucasians (5 mg/12 h; 10 mg/24 h), 213 and 406 nmol l-1 h in the Caucasian school children (10 mg; 20 mg), 87.4 and 202 nmol l-1 h in the Oriental preschool children (2.5 mg; 5 mg), and 356 and 640 nmol l-1 h in the Oriental school children (10 mg; 20 mg).",Pharmacokinetics of bambuterol during oral administration to asthmatic children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510139/),[h·nM] / [l],128,175793,DB00871,Terbutaline
,10510139,AUC,"Mean AUC of terbutaline was 128 and 242 nmol l-1 h in the preschool Caucasians (5 mg/12 h; 10 mg/24 h), 213 and 406 nmol l-1 h in the Caucasian school children (10 mg; 20 mg), 87.4 and 202 nmol l-1 h in the Oriental preschool children (2.5 mg; 5 mg), and 356 and 640 nmol l-1 h in the Oriental school children (10 mg; 20 mg).",Pharmacokinetics of bambuterol during oral administration to asthmatic children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510139/),[h·nM] / [l],242,175794,DB00871,Terbutaline
,10510139,AUC,"Mean AUC of terbutaline was 128 and 242 nmol l-1 h in the preschool Caucasians (5 mg/12 h; 10 mg/24 h), 213 and 406 nmol l-1 h in the Caucasian school children (10 mg; 20 mg), 87.4 and 202 nmol l-1 h in the Oriental preschool children (2.5 mg; 5 mg), and 356 and 640 nmol l-1 h in the Oriental school children (10 mg; 20 mg).",Pharmacokinetics of bambuterol during oral administration to asthmatic children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510139/),[h·nM] / [l],213,175795,DB00871,Terbutaline
,10510139,AUC,"Mean AUC of terbutaline was 128 and 242 nmol l-1 h in the preschool Caucasians (5 mg/12 h; 10 mg/24 h), 213 and 406 nmol l-1 h in the Caucasian school children (10 mg; 20 mg), 87.4 and 202 nmol l-1 h in the Oriental preschool children (2.5 mg; 5 mg), and 356 and 640 nmol l-1 h in the Oriental school children (10 mg; 20 mg).",Pharmacokinetics of bambuterol during oral administration to asthmatic children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510139/),[h·nM] / [l],406,175796,DB00871,Terbutaline
,10510139,AUC,"Mean AUC of terbutaline was 128 and 242 nmol l-1 h in the preschool Caucasians (5 mg/12 h; 10 mg/24 h), 213 and 406 nmol l-1 h in the Caucasian school children (10 mg; 20 mg), 87.4 and 202 nmol l-1 h in the Oriental preschool children (2.5 mg; 5 mg), and 356 and 640 nmol l-1 h in the Oriental school children (10 mg; 20 mg).",Pharmacokinetics of bambuterol during oral administration to asthmatic children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510139/),[h·nM] / [l],87.4,175797,DB00871,Terbutaline
,10510139,AUC,"Mean AUC of terbutaline was 128 and 242 nmol l-1 h in the preschool Caucasians (5 mg/12 h; 10 mg/24 h), 213 and 406 nmol l-1 h in the Caucasian school children (10 mg; 20 mg), 87.4 and 202 nmol l-1 h in the Oriental preschool children (2.5 mg; 5 mg), and 356 and 640 nmol l-1 h in the Oriental school children (10 mg; 20 mg).",Pharmacokinetics of bambuterol during oral administration to asthmatic children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510139/),[h·nM] / [l],202,175798,DB00871,Terbutaline
,10510139,AUC,"Mean AUC of terbutaline was 128 and 242 nmol l-1 h in the preschool Caucasians (5 mg/12 h; 10 mg/24 h), 213 and 406 nmol l-1 h in the Caucasian school children (10 mg; 20 mg), 87.4 and 202 nmol l-1 h in the Oriental preschool children (2.5 mg; 5 mg), and 356 and 640 nmol l-1 h in the Oriental school children (10 mg; 20 mg).",Pharmacokinetics of bambuterol during oral administration to asthmatic children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510139/),[h·nM] / [l],356,175799,DB00871,Terbutaline
,10510139,AUC,"Mean AUC of terbutaline was 128 and 242 nmol l-1 h in the preschool Caucasians (5 mg/12 h; 10 mg/24 h), 213 and 406 nmol l-1 h in the Caucasian school children (10 mg; 20 mg), 87.4 and 202 nmol l-1 h in the Oriental preschool children (2.5 mg; 5 mg), and 356 and 640 nmol l-1 h in the Oriental school children (10 mg; 20 mg).",Pharmacokinetics of bambuterol during oral administration to asthmatic children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10510139/),[h·nM] / [l],640,175800,DB00871,Terbutaline
,21944891,UTER0.5,"The mean (SD) UTER0.5 following AERO and SIDE was 9.4 (3.7) and 10.4 (4.1) μg with a mean ratio (90% confidence interval) of 89.7 (87.8, 92.3)%.",The relative lung and systemic bioavailability of terbutaline following nebulisation in non-invasively ventilated patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21944891/),μg,9.4,190805,DB00871,Terbutaline
,21944891,UTER0.5,"The mean (SD) UTER0.5 following AERO and SIDE was 9.4 (3.7) and 10.4 (4.1) μg with a mean ratio (90% confidence interval) of 89.7 (87.8, 92.3)%.",The relative lung and systemic bioavailability of terbutaline following nebulisation in non-invasively ventilated patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21944891/),μg,10.4,190806,DB00871,Terbutaline
,7137520,half-life,The half-life for intravenous theophylline in these asthmatics was 7.4 +/- 0.64.,Bioavailability of theophylline from three different tablets in asthmatic patients and their bronchodilating effects in combination with terbutaline inhalation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7137520/),,7.4,191110,DB00871,Terbutaline
,10718774,terminal half-life,"The initial rate could not be assessed directly, but it was faster than that during the second phase where absorption was rate-limiting for elimination (mean terminal half-life: 16 h).",Pharmacokinetics of bambuterol during oral administration of plain tablets and solution to healthy adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10718774/),h,16,194730,DB00871,Terbutaline
,10718774,terminal half-life,Mean terminal half-life of terbutaline was 22 h and steady-state was reached within one week of bambuterol treatment.,Pharmacokinetics of bambuterol during oral administration of plain tablets and solution to healthy adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10718774/),h,22,194731,DB00871,Terbutaline
,7362089,maximal increase,The mean maximal increase in FEV1 was 0.60 liters for the tablet and 0.70 liters for the solution.,A comparison of the bronchodilator and other responses of children to oral treatment with terbutaline tablet and solution: a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7362089/),l,0.60,197635,DB00871,Terbutaline
,7362089,maximal increase,The mean maximal increase in FEV1 was 0.60 liters for the tablet and 0.70 liters for the solution.,A comparison of the bronchodilator and other responses of children to oral treatment with terbutaline tablet and solution: a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7362089/),l,0.70,197636,DB00871,Terbutaline
,7362089,maximal increase in FVC,The mean maximal increase in FVC was 0.53 liters for the tablet and 0.67 for the solution.,A comparison of the bronchodilator and other responses of children to oral treatment with terbutaline tablet and solution: a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7362089/),l,0.53,197637,DB00871,Terbutaline
,7362089,maximal increase in FVC,The mean maximal increase in FVC was 0.53 liters for the tablet and 0.67 for the solution.,A comparison of the bronchodilator and other responses of children to oral treatment with terbutaline tablet and solution: a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7362089/),,0.67,197638,DB00871,Terbutaline
,17632023,area under the curve (AUC),"The values of the area under the curve (AUC) of FEV1, FVC and IC during the administration of tulobuterol were 2.98+/-1.05, 1.81+/-0.98, 0.75+/-0.85 L h, respectively, and during the administration of salmeterol they were 6.39+/-1.12, 6.61+/-1.34, 4.28+/-0.91 L h, respectively.",Comparison of bronchodilatory properties of transdermal and inhaled long-acting beta 2-agonists. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17632023/),h·l,2.98,204217,DB00871,Terbutaline
,17632023,area under the curve (AUC),"The values of the area under the curve (AUC) of FEV1, FVC and IC during the administration of tulobuterol were 2.98+/-1.05, 1.81+/-0.98, 0.75+/-0.85 L h, respectively, and during the administration of salmeterol they were 6.39+/-1.12, 6.61+/-1.34, 4.28+/-0.91 L h, respectively.",Comparison of bronchodilatory properties of transdermal and inhaled long-acting beta 2-agonists. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17632023/),h·l,1.81,204218,DB00871,Terbutaline
,17632023,area under the curve (AUC),"The values of the area under the curve (AUC) of FEV1, FVC and IC during the administration of tulobuterol were 2.98+/-1.05, 1.81+/-0.98, 0.75+/-0.85 L h, respectively, and during the administration of salmeterol they were 6.39+/-1.12, 6.61+/-1.34, 4.28+/-0.91 L h, respectively.",Comparison of bronchodilatory properties of transdermal and inhaled long-acting beta 2-agonists. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17632023/),h·l,0.75,204219,DB00871,Terbutaline
,17632023,area under the curve (AUC),"The values of the area under the curve (AUC) of FEV1, FVC and IC during the administration of tulobuterol were 2.98+/-1.05, 1.81+/-0.98, 0.75+/-0.85 L h, respectively, and during the administration of salmeterol they were 6.39+/-1.12, 6.61+/-1.34, 4.28+/-0.91 L h, respectively.",Comparison of bronchodilatory properties of transdermal and inhaled long-acting beta 2-agonists. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17632023/),h·l,6.39,204220,DB00871,Terbutaline
,17632023,area under the curve (AUC),"The values of the area under the curve (AUC) of FEV1, FVC and IC during the administration of tulobuterol were 2.98+/-1.05, 1.81+/-0.98, 0.75+/-0.85 L h, respectively, and during the administration of salmeterol they were 6.39+/-1.12, 6.61+/-1.34, 4.28+/-0.91 L h, respectively.",Comparison of bronchodilatory properties of transdermal and inhaled long-acting beta 2-agonists. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17632023/),h·l,6.61,204221,DB00871,Terbutaline
,17632023,area under the curve (AUC),"The values of the area under the curve (AUC) of FEV1, FVC and IC during the administration of tulobuterol were 2.98+/-1.05, 1.81+/-0.98, 0.75+/-0.85 L h, respectively, and during the administration of salmeterol they were 6.39+/-1.12, 6.61+/-1.34, 4.28+/-0.91 L h, respectively.",Comparison of bronchodilatory properties of transdermal and inhaled long-acting beta 2-agonists. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17632023/),h·l,4.28,204222,DB00871,Terbutaline
,1180094,Vdbeta,"The following values for inulin were obtained Vdbeta equals 0.25 ml g-1, plasma clearance equals 2.3 ml min-1 kg-1 and bile clearance equals 0.03-0.04 ml min-1 kg-1, which mainly are in agreement with data from the literature.",The biliary excretion of 3H-inulin and 3H-terbutaline in the unanesthetized rat. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1180094/),[ml] / [g],0.25,206039,DB00871,Terbutaline
,1180094,plasma clearance,"The following values for inulin were obtained Vdbeta equals 0.25 ml g-1, plasma clearance equals 2.3 ml min-1 kg-1 and bile clearance equals 0.03-0.04 ml min-1 kg-1, which mainly are in agreement with data from the literature.",The biliary excretion of 3H-inulin and 3H-terbutaline in the unanesthetized rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1180094/),[ml] / [kg·min],2.3,206040,DB00871,Terbutaline
,1180094,bile clearance,"The following values for inulin were obtained Vdbeta equals 0.25 ml g-1, plasma clearance equals 2.3 ml min-1 kg-1 and bile clearance equals 0.03-0.04 ml min-1 kg-1, which mainly are in agreement with data from the literature.",The biliary excretion of 3H-inulin and 3H-terbutaline in the unanesthetized rat. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1180094/),[ml] / [kg·min],0.03-0.04,206041,DB00871,Terbutaline
,6586473,relative bioavailability,Mean relative bioavailability compared with plain tablets was 76-77% with 7.5 mg SR tablets and 74-80% with those of 5 mg.,Pharmacokinetics of terbutaline given in slow-release tablets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6586473/),%,76-77,206332,DB00871,Terbutaline
,6586473,relative bioavailability,Mean relative bioavailability compared with plain tablets was 76-77% with 7.5 mg SR tablets and 74-80% with those of 5 mg.,Pharmacokinetics of terbutaline given in slow-release tablets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6586473/),%,74-80,206333,DB00871,Terbutaline
,6586473,terminal half-lives,Measurements after cessation of treatment gave terminal half-lives in plasma of 11.5-23.0 h which is considerably longer than reported in the literature.,Pharmacokinetics of terbutaline given in slow-release tablets. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6586473/),h,11.5-23.0,206334,DB00871,Terbutaline
,6586473,Renal clearance,"Renal clearance averaged 140 mL/min, similar to predicted creatinine clearance.",Pharmacokinetics of terbutaline given in slow-release tablets. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6586473/),[ml] / [min],140,206335,DB00871,Terbutaline
,1526079,bioavailability,"The AUC ratio and the deconvolution methods, by use of the separate isotope data, gave bioavailability estimates of 14.5% +/- 4.1% and 12.2% +/- 3.9%, respectively.",A comparison between the semisimultaneous and the stable isotope techniques for bioavailability estimation of terbutaline in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1526079/),%,14.5,208428,DB00871,Terbutaline
,1526079,bioavailability,"The AUC ratio and the deconvolution methods, by use of the separate isotope data, gave bioavailability estimates of 14.5% +/- 4.1% and 12.2% +/- 3.9%, respectively.",A comparison between the semisimultaneous and the stable isotope techniques for bioavailability estimation of terbutaline in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1526079/),%,12.2,208429,DB00871,Terbutaline
,1526079,bioavailability,"According to the semisimultaneous method, bioavailability estimates with the same data sets were 11.8% +/- 4.5% obtained from fitting a model to the data and 11.0% +/- 3.7% by use of a combined model fitting-deconvolution procedure.",A comparison between the semisimultaneous and the stable isotope techniques for bioavailability estimation of terbutaline in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1526079/),%,11.8,208430,DB00871,Terbutaline
,1526079,bioavailability,"According to the semisimultaneous method, bioavailability estimates with the same data sets were 11.8% +/- 4.5% obtained from fitting a model to the data and 11.0% +/- 3.7% by use of a combined model fitting-deconvolution procedure.",A comparison between the semisimultaneous and the stable isotope techniques for bioavailability estimation of terbutaline in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1526079/),%,11.0,208431,DB00871,Terbutaline
,2706188,"systemic clearance, CL","2. The mean systemic clearance, CL, was 0.19 and 0.13 l h-1 kg-1 for (+)T and (-)T, respectively.",Pharmacokinetic evaluation in man of terbutaline given as separate enantiomers and as the racemate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2706188/),[l] / [h·kg],0.19,214282,DB00871,Terbutaline
,2706188,"systemic clearance, CL","2. The mean systemic clearance, CL, was 0.19 and 0.13 l h-1 kg-1 for (+)T and (-)T, respectively.",Pharmacokinetic evaluation in man of terbutaline given as separate enantiomers and as the racemate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2706188/),[l] / [h·kg],0.13,214283,DB00871,Terbutaline
,2706188,clearance,The mean clearance of (+/-)T was 0.20 l h-1 kg-1.,Pharmacokinetic evaluation in man of terbutaline given as separate enantiomers and as the racemate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2706188/),[l] / [h·kg],0.20,214284,DB00871,Terbutaline
,2706188,Volumes of distribution,Volumes of distribution were similar (1.9 l kg-1) after the three intravenous administrations.,Pharmacokinetic evaluation in man of terbutaline given as separate enantiomers and as the racemate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2706188/),[l] / [kg],1.9,214285,DB00871,Terbutaline
,2706188,Oral bioavailability,"4. Oral bioavailability, calculated from plasma data, of (+)T was 7.5% and that of (-)T was 14.8%.",Pharmacokinetic evaluation in man of terbutaline given as separate enantiomers and as the racemate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2706188/),%,7.5,214286,DB00871,Terbutaline
,2706188,Oral bioavailability,"4. Oral bioavailability, calculated from plasma data, of (+)T was 7.5% and that of (-)T was 14.8%.",Pharmacokinetic evaluation in man of terbutaline given as separate enantiomers and as the racemate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2706188/),%,14.8,214287,DB00871,Terbutaline
,12584861,AUC0-t,The pharmacokinetic parameters of domestic and imported bambuteral: AUC0-t were (52 +/- 21) microgram.,[Bioequivalence of bambuteral and its metabolites terbutaline after oral bambuteral tablet in healthy volunteers by HPLC/MS]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584861/),μg,52,215375,DB00871,Terbutaline
,12584861,Tmax,"h.L-1, Tmax were (2.9 +/- 0.9) h and (2.6 +/- 0.7) h, Cmax were (6.0 +/- 2.6) microgram.L-1 and (6.2 +/- 2.9) microgram.",[Bioequivalence of bambuteral and its metabolites terbutaline after oral bambuteral tablet in healthy volunteers by HPLC/MS]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584861/),h,2.9,215376,DB00871,Terbutaline
,12584861,Tmax,"h.L-1, Tmax were (2.9 +/- 0.9) h and (2.6 +/- 0.7) h, Cmax were (6.0 +/- 2.6) microgram.L-1 and (6.2 +/- 2.9) microgram.",[Bioequivalence of bambuteral and its metabolites terbutaline after oral bambuteral tablet in healthy volunteers by HPLC/MS]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584861/),h,2.6,215377,DB00871,Terbutaline
,12584861,Cmax,"h.L-1, Tmax were (2.9 +/- 0.9) h and (2.6 +/- 0.7) h, Cmax were (6.0 +/- 2.6) microgram.L-1 and (6.2 +/- 2.9) microgram.",[Bioequivalence of bambuteral and its metabolites terbutaline after oral bambuteral tablet in healthy volunteers by HPLC/MS]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584861/),[μg] / [l],6.0,215378,DB00871,Terbutaline
,12584861,Cmax,"h.L-1, Tmax were (2.9 +/- 0.9) h and (2.6 +/- 0.7) h, Cmax were (6.0 +/- 2.6) microgram.L-1 and (6.2 +/- 2.9) microgram.",[Bioequivalence of bambuteral and its metabolites terbutaline after oral bambuteral tablet in healthy volunteers by HPLC/MS]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584861/),μg,6.2,215379,DB00871,Terbutaline
,12584861,T1/2Ke,"L-1, T1/2Ke were (11.2 +/- 2.3) h and (11.2 +/- 1.9) h, respectively; terbutaline: AUC0-t were (191 +/- 30) microgram.",[Bioequivalence of bambuteral and its metabolites terbutaline after oral bambuteral tablet in healthy volunteers by HPLC/MS]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584861/),h,11.2,215380,DB00871,Terbutaline
,12584861,T1/2Ke,"L-1, T1/2Ke were (11.2 +/- 2.3) h and (11.2 +/- 1.9) h, respectively; terbutaline: AUC0-t were (191 +/- 30) microgram.",[Bioequivalence of bambuteral and its metabolites terbutaline after oral bambuteral tablet in healthy volunteers by HPLC/MS]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584861/),h,11.2,215381,DB00871,Terbutaline
,12584861,AUC0-t,"L-1, T1/2Ke were (11.2 +/- 2.3) h and (11.2 +/- 1.9) h, respectively; terbutaline: AUC0-t were (191 +/- 30) microgram.",[Bioequivalence of bambuteral and its metabolites terbutaline after oral bambuteral tablet in healthy volunteers by HPLC/MS]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584861/),μg,191,215382,DB00871,Terbutaline
,12584861,Tmax,h.L-1; Tmax were (4.2 +/- 1.0) h and (4.2 +/- 1.0) h; Cmax were (10 +/- 5) microgram.,[Bioequivalence of bambuteral and its metabolites terbutaline after oral bambuteral tablet in healthy volunteers by HPLC/MS]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584861/),h,4.2,215383,DB00871,Terbutaline
,12584861,Cmax,h.L-1; Tmax were (4.2 +/- 1.0) h and (4.2 +/- 1.0) h; Cmax were (10 +/- 5) microgram.,[Bioequivalence of bambuteral and its metabolites terbutaline after oral bambuteral tablet in healthy volunteers by HPLC/MS]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584861/),μg,10,215384,DB00871,Terbutaline
,12584861,T1/2Ke,"L-1; T1/2Ke were (20 +/- 3) h and (21 +/- 4) h, respectively.",[Bioequivalence of bambuteral and its metabolites terbutaline after oral bambuteral tablet in healthy volunteers by HPLC/MS]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584861/),h,20,215385,DB00871,Terbutaline
,12584861,T1/2Ke,"L-1; T1/2Ke were (20 +/- 3) h and (21 +/- 4) h, respectively.",[Bioequivalence of bambuteral and its metabolites terbutaline after oral bambuteral tablet in healthy volunteers by HPLC/MS]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584861/),h,21,215386,DB00871,Terbutaline
,12584861,bioavaiability,The bioavaiability of the domestics was 102% +/- 8% (bambuteral) and 100% +/- 12% (terbutaline).,[Bioequivalence of bambuteral and its metabolites terbutaline after oral bambuteral tablet in healthy volunteers by HPLC/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584861/),%,102,215387,DB00871,Terbutaline
,12584861,bioavaiability,The bioavaiability of the domestics was 102% +/- 8% (bambuteral) and 100% +/- 12% (terbutaline).,[Bioequivalence of bambuteral and its metabolites terbutaline after oral bambuteral tablet in healthy volunteers by HPLC/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584861/),%,100,215388,DB00871,Terbutaline
,15135092,recovery,The average recovery for terbutaline was 87.4% from plasma.,Simple determination of terbutaline in dog plasma by column-switching liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15135092/),%,87.4,220839,DB00871,Terbutaline
,447439,absorption half-lives,Short absorption half-lives of about 7 min resulted in a fast uptake of the drug.,Pharmacokinetics of terbutaline after subcutaneous administration. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/447439/),min,7,229832,DB00871,Terbutaline
,447439,Elimination constants,Elimination constants of 0.27 +/- 0.07 hr-1 were observed.,Pharmacokinetics of terbutaline after subcutaneous administration. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/447439/),1/[h],0.27,229833,DB00871,Terbutaline
,447439,elimination constant of the second phase,The elimination process was biphasic in 5 patients with a mean elimination constant of the second phase of 0.10 +/- 0.04 hr-1.,Pharmacokinetics of terbutaline after subcutaneous administration. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/447439/),1/[h],0.10,229834,DB00871,Terbutaline
,23900693,total clearance,In patients with normal renal function the total clearance of terbutaline is 2.23-3 mL/min/kg.,Pharmacokinetics of terbutaline in chronic kidney disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23900693/),[ml] / [kg·min],2.23-3,229989,DB00871,Terbutaline
,23900693,total clearance,In our population the total clearance of terbutaline was found to be 1.72 (SD: 0.49) mL/min/kg of which approximately 15 % (0.25 mL/min/kg) was renal clearance.,Pharmacokinetics of terbutaline in chronic kidney disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23900693/),[ml] / [kg·min],1.72,229990,DB00871,Terbutaline
,23900693,distribution volume at steady state,We calculated a distribution volume at steady state of 0.74 (SD: 0.22) L/kg with a terminal half-life of 7.93 (SD: 4.06) hours.,Pharmacokinetics of terbutaline in chronic kidney disease. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23900693/),[l] / [kg],0.74,229991,DB00871,Terbutaline
,23900693,terminal half-life,We calculated a distribution volume at steady state of 0.74 (SD: 0.22) L/kg with a terminal half-life of 7.93 (SD: 4.06) hours.,Pharmacokinetics of terbutaline in chronic kidney disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23900693/),h,7.93,229992,DB00871,Terbutaline
,23900693,mean residence time (MRT),The mean residence time (MRT) was 8.35 (SD: 4.93) hours.,Pharmacokinetics of terbutaline in chronic kidney disease. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23900693/),h,8.35,229993,DB00871,Terbutaline
,7140872,steady-state concentrations,"On 3 separate days theophylline was infused to defined steady-state concentrations (0, 7.5, and 15 microgram/ml, respectively) followed by the administration, at 1-h intervals, of incremental i.v. doses of terbutaline.",Separate and combined use of terbutaline and theophylline in asthmatics. Effects related to plasma levels. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140872/),[μg] / [ml],0,230473,DB00871,Terbutaline
,7140872,steady-state concentrations,"On 3 separate days theophylline was infused to defined steady-state concentrations (0, 7.5, and 15 microgram/ml, respectively) followed by the administration, at 1-h intervals, of incremental i.v. doses of terbutaline.",Separate and combined use of terbutaline and theophylline in asthmatics. Effects related to plasma levels. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140872/),[μg] / [ml],7.5,230474,DB00871,Terbutaline
,7140872,steady-state concentrations,"On 3 separate days theophylline was infused to defined steady-state concentrations (0, 7.5, and 15 microgram/ml, respectively) followed by the administration, at 1-h intervals, of incremental i.v. doses of terbutaline.",Separate and combined use of terbutaline and theophylline in asthmatics. Effects related to plasma levels. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140872/),[μg] / [ml],15,230475,DB00871,Terbutaline
,10895896,maximum serum terbutaline concentration,"Following i.v. administration, median maximum serum terbutaline concentration and mean residence time were 9.3 ng/ml and 30 minutes, respectively.",Pharmacokinetics and pharmacodynamics of terbutaline in healthy horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10895896/),[ng] / [ml],9.3,239682,DB00871,Terbutaline
,10895896,mean residence time,"Following i.v. administration, median maximum serum terbutaline concentration and mean residence time were 9.3 ng/ml and 30 minutes, respectively.",Pharmacokinetics and pharmacodynamics of terbutaline in healthy horses. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10895896/),min,30,239683,DB00871,Terbutaline
<,10895896,Bioavailability,Bioavailability following oral administration was < 1%.,Pharmacokinetics and pharmacodynamics of terbutaline in healthy horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10895896/),%,1,239684,DB00871,Terbutaline
,31677149,entrapment efficiency,The optimized TBN chitosan-coated bilosomes (TBN-CTS-BLS) were spherical vesicles (245.13 ± 10.23 nm) with adequate entrapment efficiency (65.25 ± 5.51%) and good permeation characteristics (340.11 ± 22.34 μg/cm2).,"A novel nanogel loaded with chitosan decorated bilosomes for transdermal delivery of terbutaline sulfate: artificial neural network optimization, in vitro characterization and in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31677149/),%,65.25,246104,DB00871,Terbutaline
,31677149,permeation characteristics,The optimized TBN chitosan-coated bilosomes (TBN-CTS-BLS) were spherical vesicles (245.13 ± 10.23 nm) with adequate entrapment efficiency (65.25 ± 5.51%) and good permeation characteristics (340.11 ± 22.34 μg/cm2).,"A novel nanogel loaded with chitosan decorated bilosomes for transdermal delivery of terbutaline sulfate: artificial neural network optimization, in vitro characterization and in vivo evaluation. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31677149/),[μg] / [cm2],340.11,246105,DB00871,Terbutaline
,31677149,t1/2,The pharmacokinetic study revealed that the optimized TBN-CTS-BLS formulation successively enhanced the bioavailability of TBN by about 2.33-fold and increased t1/2 to about 6.21 ± 0.24 h as compared to the oral solution.,"A novel nanogel loaded with chitosan decorated bilosomes for transdermal delivery of terbutaline sulfate: artificial neural network optimization, in vitro characterization and in vivo evaluation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31677149/),h,6.21,246106,DB00871,Terbutaline
,2776583,terminal half-life,The terminal half-life was 8.8-15.8 h.,Pharmacokinetics of intravenous terbutaline in asthmatic children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2776583/),h,8.8-15.8,253104,DB00871,Terbutaline
,2776583,Body clearance,"Body clearance was 2.73-5.44 ml/min/kg, two-thirds of which were of renal origin.",Pharmacokinetics of intravenous terbutaline in asthmatic children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2776583/),[ml] / [kg·min],2.73-5.44,253105,DB00871,Terbutaline
,2776583,volume of distribution (Vss),The volume of distribution (Vss) was 1.28-1.83 l/kg.,Pharmacokinetics of intravenous terbutaline in asthmatic children. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2776583/),[l] / [kg],1.28-1.83,253106,DB00871,Terbutaline
,6586470,CL,"Measurements up to 12 h gave estimated values for CL from 136 mL/min to 340 mL/min, for CLR from 82 mL/min to 192 mL/min, for MRT from 1.5 h to 5.6 h, and for Vss from 24 L to 73 L.",Pharmacokinetics of terbutaline after parenteral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6586470/),[ml] / [min],136,254415,DB00871,Terbutaline
,6586470,CL,"Measurements up to 12 h gave estimated values for CL from 136 mL/min to 340 mL/min, for CLR from 82 mL/min to 192 mL/min, for MRT from 1.5 h to 5.6 h, and for Vss from 24 L to 73 L.",Pharmacokinetics of terbutaline after parenteral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6586470/),[ml] / [min],340,254416,DB00871,Terbutaline
,6586470,CLR,"Measurements up to 12 h gave estimated values for CL from 136 mL/min to 340 mL/min, for CLR from 82 mL/min to 192 mL/min, for MRT from 1.5 h to 5.6 h, and for Vss from 24 L to 73 L.",Pharmacokinetics of terbutaline after parenteral administration. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6586470/),[ml] / [min],82,254417,DB00871,Terbutaline
,6586470,CLR,"Measurements up to 12 h gave estimated values for CL from 136 mL/min to 340 mL/min, for CLR from 82 mL/min to 192 mL/min, for MRT from 1.5 h to 5.6 h, and for Vss from 24 L to 73 L.",Pharmacokinetics of terbutaline after parenteral administration. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6586470/),[ml] / [min],192,254418,DB00871,Terbutaline
,6586470,MRT,"Measurements up to 12 h gave estimated values for CL from 136 mL/min to 340 mL/min, for CLR from 82 mL/min to 192 mL/min, for MRT from 1.5 h to 5.6 h, and for Vss from 24 L to 73 L.",Pharmacokinetics of terbutaline after parenteral administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6586470/),h,1.5,254419,DB00871,Terbutaline
,6586470,MRT,"Measurements up to 12 h gave estimated values for CL from 136 mL/min to 340 mL/min, for CLR from 82 mL/min to 192 mL/min, for MRT from 1.5 h to 5.6 h, and for Vss from 24 L to 73 L.",Pharmacokinetics of terbutaline after parenteral administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6586470/),h,5.6,254420,DB00871,Terbutaline
,6586470,Vss,"Measurements up to 12 h gave estimated values for CL from 136 mL/min to 340 mL/min, for CLR from 82 mL/min to 192 mL/min, for MRT from 1.5 h to 5.6 h, and for Vss from 24 L to 73 L.",Pharmacokinetics of terbutaline after parenteral administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6586470/),l,24,254421,DB00871,Terbutaline
,6586470,Vss,"Measurements up to 12 h gave estimated values for CL from 136 mL/min to 340 mL/min, for CLR from 82 mL/min to 192 mL/min, for MRT from 1.5 h to 5.6 h, and for Vss from 24 L to 73 L.",Pharmacokinetics of terbutaline after parenteral administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6586470/),l,73,254422,DB00871,Terbutaline
,6586470,Body clearance,Body clearance was now found to vary between 165 and 270 mL/min.,Pharmacokinetics of terbutaline after parenteral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6586470/),[ml] / [min],165 and 270,254423,DB00871,Terbutaline
,6586470,MRT,"MRT between 7.3 and 11.7 h, and Vss between 83 and 140 L.",Pharmacokinetics of terbutaline after parenteral administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6586470/),h,7.3 and 11.7,254424,DB00871,Terbutaline
,6586470,Vss,"MRT between 7.3 and 11.7 h, and Vss between 83 and 140 L.",Pharmacokinetics of terbutaline after parenteral administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6586470/),l,83 and 140,254425,DB00871,Terbutaline
,7842769,24-h,Mean 24-h plasma concentration was comparable for morning and evening bambuterol (13.2 vs 14.0 nmol/L).,Bambuterol in the treatment of asthma. A placebo-controlled comparison of once-daily morning vs evening administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7842769/),[nM] / [l],13.2,265425,DB00871,Terbutaline
,7842769,24-h,Mean 24-h plasma concentration was comparable for morning and evening bambuterol (13.2 vs 14.0 nmol/L).,Bambuterol in the treatment of asthma. A placebo-controlled comparison of once-daily morning vs evening administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7842769/),[nM] / [l],14.0,265426,DB00871,Terbutaline
,7842769,plasma concentration,Mean 24-h plasma concentration was comparable for morning and evening bambuterol (13.2 vs 14.0 nmol/L).,Bambuterol in the treatment of asthma. A placebo-controlled comparison of once-daily morning vs evening administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7842769/),[nM] / [l],13.2,265427,DB00871,Terbutaline
,7842769,plasma concentration,Mean 24-h plasma concentration was comparable for morning and evening bambuterol (13.2 vs 14.0 nmol/L).,Bambuterol in the treatment of asthma. A placebo-controlled comparison of once-daily morning vs evening administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7842769/),[nM] / [l],14.0,265428,DB00871,Terbutaline
,7842769,Cmax,The Cmax for evening vs morning dosing was 17.2 vs 15.5 nmol/L (p < 0.02).,Bambuterol in the treatment of asthma. A placebo-controlled comparison of once-daily morning vs evening administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7842769/),[nM] / [l],17.2,265429,DB00871,Terbutaline
,7842769,Cmax,The Cmax for evening vs morning dosing was 17.2 vs 15.5 nmol/L (p < 0.02).,Bambuterol in the treatment of asthma. A placebo-controlled comparison of once-daily morning vs evening administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7842769/),[nM] / [l],15.5,265430,DB00871,Terbutaline
,7784338,inhaled flow,Measurements were carried out with a pMDI at slow (27 l/min) and fast (151 l/min) inhaled flows and with Nebuhaler large volume spacer device (average inhaled flow 17 l/min).,Comparison of gamma scintigraphy and a pharmacokinetic technique for assessing pulmonary deposition of terbutaline sulphate delivered by pressurized metered dose inhaler. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7784338/),[l] / [min],17,271705,DB00871,Terbutaline
,23883311,relative bioavailability,The film formula of choice gave a significantly faster drug absorption rate and recorded a relative bioavailability of 204.08%.,Fast-dissolving sublingual films of terbutaline sulfate: formulation and in vitro/in vivo evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23883311/),%,204.08,273406,DB00871,Terbutaline
